#Oncology/Cancer Drugs Oncology/Cancer Drugs Market Application Oncology/Cancer Drugs Market Drivers Oncology/Cancer Drugs Market Dynamics O
Explore tagged Tumblr posts
Visit Tumblr Blog
Explore Tumblr blogs with no restrictions, modern design and the best experience.
Last Seen Tumblr Blogs
Fun Fact
Forty percent of Tumblr users are between the ages of 18 to 25.
Text
MRD Testing Market Future Trends to Look Out | Bis Research
MRD Testing is a sophisticated diagnostic technique used primarily in oncology to detect and quantify residual cancer cells that may remain in the body during or after treatment.
The global MRD Testing Market is a rapidly growing segment in the healthcare industry, driven by the increasing demand for accurate and sensitive methods to monitor and manage cancer patients.
The MRD Testing market was valued at $1.67 billion in 2023 and is expected to reach $6.67 billion by 2033, growing at a CAGR of 14.81% between 2023 and 2033.
MRD Testing Overview
MRD Testing refers to the detection and quantification of residual cancer cells that remain in a patient after treatment, which are below the detection threshold of conventional diagnostic methods. MRD testing is particularly significant in hematologic malignancies such as leukemia, lymphoma, and multiple myeloma, where even a small number of remaining cancer cells can lead to relapse.
Have a look at our sample page here !
Market Segmentation
By Technology
By Target Detection
By End Users
By Region
China dominated the Asia-Pacific MRD market in 2022 with a share of 36.08%. Although the market is expected to remain in a strong growth phase due to the massively growing number of cancer cases and the rising health-related awareness among people in Asia-Pacific, a significant barrier to the increasing adoption is an uneven economic balance among countries within the region.
Importance of MRD Testing Market
Assessing Treatment Response
Predicting Relapse
Tailoring Therapy
Key Factors
The MRD Testing market has experienced significant growth in recent years, driven by several key factors like
advancements in technology
rising cancer burden,
clinical evidence supporting MRD monitoring
Key Players In the MRD Testing Market includes
QIAGEN N.V.
Thermo Fisher Scientific Inc.
Sysmex Corporation
Mission Bio
OPKO Health
Bio-Rad Laboratories, Inc
ICON plc
Hoffmann-La Roche
and many others
Techniques used in MRD Testing
Flow Cytometry - This technique uses fluorescent antibodies to identify cancer-specific markers on the surface of cells.
Polymerase Chain Reaction- PCR amplifies cancer-specific genetic sequences, allowing for the detection of one cancer cell among a million normal cells.
Next Generation Sequencing - NGS provides detailed genetic information by sequencing DNA or RNA at high depth, offering unparalleled sensitivity and the ability to identify clonal diversity and mutations.
Digital Droplet PCR- A more recent advancement, ddPCR partitions the sample into thousands of droplets and performs PCR on each droplet individually, providing high sensitivity and precise quantification.
Applications for MRD Testing Market
Treatment Response Monitoring
Relapse Prediction
Treatment Decision-making
Prognostic Assessment
Clinical Trials and drug development
MRD Testing Market Dynamics
Market Drivers
Advent of MRD and its Awareness among Consumers
Increasing Incidence of Cancer Cases Demanding MRD
Rise in administration of solid tumors
Expanding Medicare Coverage for MRD
Recent Developments in the MRD Testing Market
•Quest Diagnostics acquired Haystack Oncology, expanding its oncology portfolio with the inclusion of advanced liquid biopsy technology. This addition aimed to enhance personalized cancer care by offering highly sensitive diagnostic capabilities. Integrated DNA Technologies launched the Archer FUSIONPlex Core Solid Tumor Panel, a pioneering cancer research testing solution that has been enhanced and fine-tuned to include a broader range of single nucleotide variant (SNV) and indel coverage.
Visit our precision medicine page here!
Key Questions Answered
Q What is MRD ?
Minimal residual disease (MRD) testing is a supplementary approach to detect extremely low levels of blood cancer cells and solid tumors following the treatment of conditions such as acute and chronic leukemia, lymphoma, or multiple myeloma. MRD specifically pertains to the minute population of cancer cells that persist in the body despite achieving complete remission (CR) through chemotherapy or stem cell transplantation.
Q What kinds of New Strategies are adopted by the existing market players to strengthen their positions in the Industry ?
The global MRD market is currently witnessing several developments, primarily aimed at introducing new products and services. Major manufacturers of MRD products, along with the service providers, are actively undertaking significant business strategies to translate success in research and development into the commercial clinical setting.
Conclusion
In conclusion, MRD testing is a powerful tool in modern oncology, offering the potential to significantly improve patient outcomes through more precise and personalized treatment strategies.
0 notes
Text
Oncology/Cancer Drugs Market 2021 Investment Opportunity Analysis and Industry Share Forecast 2027
"
Oncology/Cancer Drugs Market is analyzed with industry experts in mind to maximize return on investment by providing clear information needed for informed business decisions. This research will help both established and new entrants to identify and analyze market needs, market size and competition. It explains the supply and demand situation, the competitive scenario, and the challenges for market growth, market opportunities and the threats faced by key players.
Sample Copy of This Report:https://axelreports.com/request-sample/54358
A 360 degree outline of the competitive scenario of the Global Oncology/Cancer Drugs Market is presented by Axel Reports Market Insights. It has a massive data allied to the recent product and technological developments in the markets.
It has a wide-ranging analysis of the impact of these advancements on the market’s future growth, wide-ranging analysis of these extensions on the market’s future growth. The research report studies the market in a detailed manner by explaining the key facets of the market that are foreseeable to have a countable stimulus on its developing extrapolations over the forecast period.
Reasons for buying this report:
It offers an analysis of changing competitive scenario.
For making informed decisions in the businesses, it offers analytical data with strategic planning methodologies.
It offers seven-year assessment of Global Oncology/Cancer Drugs
It helps in understanding the major key product segments.
Researchers throw light on the dynamics of the market such as drivers, restraints, trends, and opportunities.
It offers regional analysis of Global Oncology/Cancer Drugs Market along with business profiles of several stakeholders.
It offers massive data about trending factors that will influence the progress of the Global Oncology/Cancer Drugs
Get ToC for the overview of the premium report @ https://axelreports.com/industry-analysis/2021-2027-global-and-regional-oncology-c/54358
By Market Players: Roche Novartis QILU HENGRUI LUYE AstraZeneca Lunan HANSOH Sanofi GuiZhou YiBai Eli Lilly and Company By Type Antimetabolite Alkaloid drugs Hormone Targeted drug Platinum-based drugs Other By Application Blood Cancer Breast Cancer Gastrointestinal Cancer Prostate Cancer Respiratory/Lung Cancer Other
A detailed outline of the Global Oncology/Cancer Drugs Market includes a comprehensive analysis of different verticals of businesses. North America, Latin America, Asia-Pacific, Africa, and Europe have been considered for the studies on the basis of several terminologies.
This is anticipated to drive the Global Oncology/Cancer Drugs Market over the forecast period. This research report covers the market landscape and its progress prospects in the near future. After studying key companies, the report focuses on the new entrants contributing to the growth of the market. Most companies in the Global Oncology/Cancer Drugs Market are currently adopting new technological trends in the market.
Finally, the researchers throw light on different ways to discover the strengths, weaknesses, opportunities, and threats affecting the growth of the Global Oncology/Cancer Drugs Market. The feasibility of the new report is also measured in this research report.
Make an Enquiry for purchasing this Report :https://axelreports.com/enquiry-before-buying/54358
Table of Contents:
Global Oncology/Cancer Drugs Market Overview
Economic Impact on Industry
Market Competition by Manufacturers
Production, Revenue (Value) by Region
Production, Revenue (Value), Price Trend by Type
Market Analysis by Application
Cost Analysis
Industrial Chain, Sourcing Strategy and Downstream Buyers
Marketing Strategy Analysis, Distributors/Traders
Market Effect Factors Analysis
Global Oncology/Cancer Drugs Market Forecast
ABOUT US:
Axel Reports has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the world’s most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.
Contact: Axel Reports Akansha G (Knowledge Partner) Office No- B 201 Pune, Maharashtra 411060 Phone: US +18488639402 Email: [email protected]/ Web: https://axelreports.com/
"
1 note
·
View note
Text
Biomarkers Market- What will be the Short-term Impact of Coronavirus?
The global “biomarkers market” is set to gain traction from their increasing usage in a wide variety of applications, namely, drug discovery and development, safety assessment, and medicine. Besides, numerous biotech and pharmaceutical companies are persistently investing huge sums in the research and development activities. The increasing prevalence of cancer is also one of the crucial factors that would affect the market positively during the forecast period.
Click here to get the short-term and long-term impact of COVID-19 on this Biomarkers Market.
Please visit: https://www.fortunebusinessinsights.com/biomarkers-market-102173
Detailed Table of Content:
· Introduction
o Research Scope
o Market Segmentation
o Research Methodology
o Definitions and Assumptions
· Executive Summary
· Market Dynamics
o Market Drivers
o Market Restraints
o Market Opportunities
· Key Insights
o New Product Launches, by Key Market Players
o Prevalence by Disease Indication, By Key Countries/ Region, 2018
o Incidence of Cancer, By Key Countries/ Key Region,2018
o Key industry Developments - Mergers, Acquisitions and Partnerships
o Overview of Biomarkers In Personalized Medicine
· Global Biomarkers Market Analysis, Insights and Forecast, 2015-2026
o Key Findings / Summary
o Market Analysis, Insights and Forecast – By Indication
§ Oncology
§ Cardiology
§ Neurology
§ Others
o Market Analysis, Insights and Forecast – By End User
§ Pharmaceutical & Biotechnology Companies
§ Diagnostics & Research Laboratories
§ Hospitals & Specialty Clinics
§ Others
o Market Analysis, Insights and Forecast – By Region
§ North America
§ Europe
§ Asia Pacific
§ Latin America
§ Middle East & Africa
Automotive Infotainment Market
Autonomous Emergency Braking Market
Automotive Piston Market
Automotive Fuel Tank Market
Advanced Parking Management System Market
Automotive Electronics Market
Automotive Instrument Cluster Market
Clutch Disc Market
Automotive Catalytic Converter Market
0 notes
Text
Monoclonal Antibody Therapeutics Market Analysis (2020-2027)
Different monoclonal antibodies with unique mechanism of actions have been approved over the past few years, which work on immune checkpoints such as CTLA-4, PD-1, and PD-L1. Manufacturers are focusing on developing drugs belonging to various classes in order to treat variety of diseases ranging from cancer to rare diseases. Monoclonal antibody coupled with chemotherapy agents is becoming a viable treatment option to treat various cancers. For instance, in 2017, the U.S. Food & Drug Administration (FDA) approved Darzalex (daratumumab) in combination with pomalidomide and dexamethasone for the treatment of patients suffering from multiple myeloma, who have received two prior therapies. These factors are expected to support growth of the market over the forecast period.
Market Dynamics
Rising incidence of cancer and other chronic diseases is a major factor that is expected to boost the monoclonal antibodies market growth over the forecast period. According to GLOBOCAN, in 2018, an estimated 43.6% new cases of breast cancer were registered in Asia Pacific. Also, according to the American Cancer Society, 2017, cancer was the second most common cause of death in the U.S., which accounted for around 1 out of every 4 deaths.
Market players are focused on combining monoclonal antibodies with other therapies such as chemotherapy drugs, which is expected to assist the market growth over the forecast period. For instance, combination of nivolumab and ipilimumab for the treatment of intermediate- or poor-risk patients with previously untreated advanced renal cell carcinoma was approved in the U.S. in 2018 and in January 2019 in Europe.
Moreover, efforts of manufacturers to increase number of indications (oncology) for monoclonal antibodies is further expected to boost the market growth over the forecast period. For instance, in June 2018, the U.S. Food & Drug Administration (FDA) expanded the indication of pembrolizumab (Keytruda) to include recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
Key features of the study:
· This report provides in-depth analysis of the global monoclonal antibodies market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
· It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
· This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
· It profiles key players in the global monoclonal antibodies market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
· Key companies covered as a part of this study include Pfizer Inc., Novartis AG, Bayer AG, Sanofi S.A., F. Hoffmann-La Roche AG, Eli Lilly and Co., Merck & Co., Inc., GlaxoSmithKline Plc., AbbVie Inc., Bristol-Myers Squibb, and Regeneron Pharmaceuticals Inc.
· Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future launches, market expansion, and marketing tactics
· The global monoclonal antibodies market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
· Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global monoclonal antibodies market
Detailed Segmentation:
· Global Monoclonal Antibodies Market, By Source:
o Human
o Chimeric
o Murine
o Humanized
· Global Monoclonal Antibodies Market, By Application:
o Cancer
o Autoimmune Disease
o Hematological Disease
o Infectious Disease
o Others
· Global Monoclonal Antibodies Market, By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
· Global Monoclonal Antibodies Market, By Region:
o North America
§ By Source:
§ Human
§ Chimeric
§ Murine
§ Humanized
§ By Application:
§ Cancer
§ Autoimmune Disease
§ Hematological Disease
§ Infectious Disease
§ Others
§ By Distribution Channel:
§ Hospital Pharmacies
§ Retail Pharmacies
§ Online Pharmacies
§ By Country:
§ U.S.
§ Canada
o Latin America
§ By Source:
§ Human
§ Chimeric
§ Murine
§ Humanized
§ By Application:
§ Cancer
§ Autoimmune Disease
§ Hematological Disease
§ Infectious Disease
§ Others
§ By Distribution Channel:
§ Hospital Pharmacies
§ Retail Pharmacies
§ Online Pharmacies
§ By Country:
§ Brazil
§ Mexico
§ Argentina
§ Rest of Latin America
o Europe
§ By Source:
§ Human
§ Chimeric
§ Murine
§ Humanized
§ By Application:
§ Cancer
§ Autoimmune Disease
§ Hematological Disease
§ Infectious Disease
§ Others
§ By Distribution Channel:
§ Hospital Pharmacies
§ Retail Pharmacies
§ Online Pharmacies
§ By Country:
§ Germany
§ U.K.
§ France
§ Italy
§ Spain
§ Russia
§ Rest of Europe
o Asia Pacific
§ By Source:
§ Human
§ Chimeric
§ Murine
§ Humanized
§ By Application:
§ Cancer
§ Autoimmune Disease
§ Hematological Disease
§ Infectious Disease
§ Others
§ By Distribution Channel:
§ Hospital Pharmacies
§ Retail Pharmacies
§ Online Pharmacies
§ By Country:
§ China
§ India
§ Japan
§ Australia
§ South Korea
§ ASEAN
§ Rest of Asia Pacific
o Middle East
§ By Source:
§ Human
§ Chimeric
§ Murine
§ Humanized
§ By Application:
§ Cancer
§ Autoimmune Disease
§ Hematological Disease
§ Infectious Disease
§ Others
§ By Distribution Channel:
§ Hospital Pharmacies
§ Retail Pharmacies
§ Online Pharmacies
§ By Country:
§ GCC
§ Israel
§ Rest of Middle East
o Africa
§ By Source:
§ Human
§ Chimeric
§ Murine
§ Humanized
§ By Application:
§ Cancer
§ Autoimmune Disease
§ Hematological Disease
§ Infectious Disease
§ Others
§ By Distribution Channel:
§ Hospital Pharmacies
§ Retail Pharmacies
§ Online Pharmacies
§ By Country/Region:
§ South Africa
§ Central Africa
§ North Africa
· Company Profiles
o Pfizer Inc.*
§ Company Overview
§ Product Portfolio
§ Financial Performance
§ Key Highlights
§ Market Strategies
o Novartis AG
o Bayer AG
o Sanofi S.A.
o Hoffmann-La Roche AG
o Eli Lilly and Co.
o Merck & Co., Inc.
o GlaxoSmithKline Plc.
o AbbVie Inc.
o Bristol-Myers Squibb
o Regeneron Pharmaceuticals Inc.
Request sample copy here :
https://www.coherentmarketinsights.com/insight/request-sample/2403
Request PDF brochure here:
https://www.coherentmarketinsights.com/insight/request-pdf/2403
Click here to buy: https://www.coherentmarketinsights.com/insight/buy-now/2403
CMI Services: https://www.coherentmarketinsights.com/services
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.
What we provide:
· Customized Market Research Services
· Industry Analysis Services
· Business Consulting Services
· Market Intelligence Services
· Long term Engagement Model
· Country Specific Analysis
Contact Us:
Mr. Shah
Coherent Market Insights Pvt. Ltd.
Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S.
Phone: +1-206-701-6702
Email : [email protected]
Reference/Source: https://www.coherentmarketinsights.com/market-insight/monoclonal-antibody-therapeutics-market-2403
0 notes
Text
Global Kidney Cancer Drugs Market : Industry Analysis and forecast 2019 – 2027: By Type, Therapy, Distribution Channel, and Region.
Global Kidney Cancer Drugs Market size was valued US$ XX Bn. in 2019 and the total revenue is expected to grow at XX% from 2019 to 2027, reaching nearly US$ 7.5 Bn.
The report study has analyzed the revenue impact of COVID-19 pandemic on the sales revenue of market leaders, market followers, and market disrupters in the report, and the same is reflected in our analysis.
Kidney cancer also called renal cancer, affects kidney cells to grow out of control and limit the function of normal cells. It is one of the sixth common cancers observed in men and the tenth most common cause of cancer for women. The two main types of kidney cancer are Transitional Cell Carcinoma (TCC) and Renal Cell Carcinoma (RCC) of the renal pelvis.
The MMR report covers all the trends and technologies playing a major role in the growth of the kidney cancer drugs market over 2019-2027. It also highlights the drivers, restraints, and opportunities expected to influence market growth during the forecast period. Major companies operating in the market are focusing on commercial expansion and clinical collaboration present in the market. Stringent governmental regulation makes kidney cancer drugs market tough for small players. A small player or new startup companies in the market are launching various bio-similar products in order to satisfy the growing demand from the emerging economies of the world. On the other hand, lack of appropriate regulatory standards for drug prescriptions and preferences of people for cost-effective generic kidney cancer drugs are major factors expected to hinder the growth of the global market for kidney cancer drugs over 2019-2027.
By therapy, immunotherapy segment was valued US$ XX.22 Mn in 2019 and is expected to reach US$ XX.40 Mn by 2027 at a CAGR of XX.32% over the forecast period. Introduction of advanced drugs, for example, immunotherapy and immune-oncologic are expected to increase the adoption rate as these new drugs are more effective than targeted therapies to a precise patient subpopulation.
The report offers a brief analysis of the major regions in the global kidney cancer drugs market, namely, Europe, North America, Asia-Pacific, Middle East & Africa, and Latin America. North America is expected to continue to hold the largest XX% share in kidney cancer drugs. This is owing to an increased base population of kidney cancer, and a large presence of main drug manufacturers in the USA, which are responsible for launching new drug medication for kidney cancer or renal cancer.
As per the American Cancer Society study in the U.S., approximately 63,990 adults’ new cases of kidney cancer will be diagnosed. The average age of diagnosis is 64 and is hardly found in people less than 45. It is projected that nearly 66% of people are diagnosed when the cancer is only located in the kidney and the five-year survival rate is 92% in this group. The incidence of renal cell cancer is observed highest in Europe and North America. Approximately 59% of kidney cancer cases are observed in developed economies. Thus, increasing the incidence of kidney cancer and the entry of new drug treatment are the key factors contributing to the growth of the kidney cancer drug market globally.
The report covers key developments in the kidney cancer drug market as organic and inorganic growth strategies. In November 2018, Roche Company has withdrawn an application to the European Medicines Agency (EMA) for extended use for its immunotherapy drug, Tecentriq. The Swiss pharma firm had been learning the effects of programmed death-ligand 1 (PD-L1) inhibitor Tecentriq in combination with Avastin to treat kidney cancer.
The objective of the report is to present a comprehensive analysis of the Global Kidney Cancer Drugs Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global Kidney Cancer Drugs Market dynamics, structure by analyzing the market segments and projects the Global Kidney Cancer Drugs Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Kidney Cancer Drugs Market make the report investor’s guide.
Global Kidney Cancer Drugs Market Request For View Sample Report Page :@https://www.maximizemarketresearch.com/request-sample/66282
Scope of the Global Kidney Cancer Drugs Market
Global Kidney Cancer Drugs Market, by Type
• Inlyta (Axitinib) • Afinitor (Everolimus) • Votrient (Pazopanib) • Sutent (Sunitinib) • Nexavar (Sorafenib) • Avastin (Bevacizumab) • Torisel (Temsirolimus) • Proleukin (Interlukin-2/Aldesleukin) Global Kidney Cancer Drugs Market, by Therapy
• Targeted Therapy o Approved drugs o Pipeline drugs • Chemotherapy • Immunotherapy Global Kidney Cancer Drugs Market, by Distribution Channel
• Hospital Pharmacies • E-commerce • Drug stores • Retail pharmacy Global Kidney Cancer Drugs Market, by Region
• Asia Pacific • North America • Europe • South America • Middle East & Africa Key players operating in the Global Kidney Cancer Drugs Market
• Bayer • Amgen • Novartis • Roche • Active Biotech • GlaxoSmithKline • ArQule • Abbott Laboratories • Pfizer • Argos Therapeutics • Exelixis • Cipla Limited • AVEO Pharmaceuticals • Onyx Therapeutics • Genentech • Cerulean Pharma • Bionomics • immatics biotechnologies • Bristol-Myers Squibb • Oxford BioMedica • Wilex • Tracon Pharmaceuticals • Taiwan Liposome • Prometheus Laboratories • Seattle Genetics
Global Kidney Cancer Drugs Market Do Inquiry Before Purchasing Report Here @ :https://www.maximizemarketresearch.com/inquiry-before-buying/66282 About Us:
Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.
Contact info: Name: Vikas Godage Organization: Maximize Market Research Pvt.Ltd.Pune Email: [email protected] Contact: +919607065656 / +919607195908 Website:www.maximizemarketresearch.com
0 notes
Text
Cancer Therapeutics Market Key Players F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Inc. Johnson & Johnson, Celgene Corporation-Astellas Pharma, Inc and o
KD Market research has presented a detailed report on “Cancer Therapeutics Market” which includes the major application, advantages, and key market trends that are fostering the growth of the market during the forecasted span of 6 years. The research takes a step forward and analyzes the key competitors and global regions that are holding the market share of Cancer Therapeutics Market in terms of revenue.
The use of targeted, biologic (immunotherapy) & other forms of therapies administered to treat cancer through oncology drugs is known as cancer therapeutics. The global cancer therapeutics market was valued at $81,291 million in 2016 and is estimated to reach at $178,863 million by 2023, registering a CAGR of 11.9% from 2017 to 2023.
Request sample copy of this Report@ https://www.kdmarketresearch.com/sample/3201
Upsurge in collaboration between pharmaceutical companies, rise in cancer awareness & availability of oncology drugs, increase in cancer funding & research, and growth in geriatric population are the key factors that augment the growth of the cancer therapeutics market. Furthermore, rise in prevalence of cancer cases is expected to boost the market growth.
However, adverse effects associated with cancer therapeutics market and high costs associated with oncology drug development are some of the factors that impede the market growth. Conversely, the high potential of emerging economies and increase in demand for personalized medicine is expected to provide new opportunities for the market players in future.
The cancer therapeutics market is segmented based on application, top selling drugs, and region. Based on application, the market is divided into blood cancer, lung cancer, colorectal cancer, prostate cancer, breast cancer, cervical cancer, and others. By top selling drugs, it is categorized into Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, and others. Region wise, it is analyzed across the North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
-This report entails a detailed quantitative analysis of the current market trends from 2016 to 2023 to identify the prevailing opportunities along with strategic assessment of global cancer therapeutics market.
-Cancer therapeutics market size and market estimations are based on comprehensive analysis of the applications, top selling drugs, and developments in the industry.
-An in-depth analysis based on region assists to understand the regional market and facilitate the strategic business planning.
-The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.
KEY MARKET SEGMENTS
By Application - Blood Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Others
By Top Selling Drugs - Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, Others
By Region - North America, U.S., Canada, Europe, Germany, France, UK, Italy, Spain, Rest of Europe, Asia-Pacific, Japan, China, India, Rest of Asia-Pacific, LAMEA, Latin America, Middle-East, Africa The list of key players operating in this market include:
· F. Hoffmann-La Roche AG
· Bristol-Myers Squibb Company
· AbbVie, Inc.
· Johnson & Johnson
· Celgene Corporation-Astellas Pharma, Inc.
· Pfizer, Inc.
· Novartis AG
· Merck KGaA
· Eli Lilly and Company
Browse Complete Research Report with toc@ https://www.kdmarketresearch.com/report/3201/cancer-therapeutics-market-amr
Table of Content
CHAPTER 1: INTRODUCTION
1.1. Report description 1.2. Key benefits for stakeholders 1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research 1.4.2. Primary research 1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. KEY FINDINGS OF THE STUDY 2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope 3.2. Key findings
3.2.1. Top investment pockets 3.2.2. Top winning strategies
3.3. Market share analysis, 2016 3.4. Porters five forces analysis 3.5. Clinical trials 3.6. Market dynamics
3.6.1. Drivers
3.6.1.1. Increase in prevalence of cancer 3.6.1.2. Surge in cancer research 3.6.1.3. Rise in strategic acquisitions and collaborations
3.6.2. Restraints
3.6.2.1. High cost of drug development and threat of failure 3.6.2.2. Adverse effects associated with cancer drug therapy
3.6.3. Opportunities
3.6.3.1. High potential associated with personalized medicines 3.6.3.2. Increase in purchasing power of emerging economics
CHAPTER 4: CANCER THERAPEUTICS MARKET, APPLICATION
4.1. Overview
4.1.1. Market size and forecast
4.2. Blood cancer
4.2.1. Key market trends, growth factors & opportunities 4.2.2. Market size and forecast, by region 4.2.3. Market analysis, by country
4.3. Lung cancer
4.3.1. Key market trends, growth factors & opportunities 4.3.2. Market size and forecast, by region 4.3.3. Market analysis, by country
4.4. Breast cancer
4.4.1. Key market trends, growth factors & opportunities 4.4.2. Market size and forecast, by region 4.4.3. Market analysis, by country
4.5. Colorectal cancer
4.5.1. Key market trends, growth factors & opportunities 4.5.2. Market size and forecast, by region 4.5.3. Market analysis, by country
4.6. Prostate cancer
4.6.1. Key market trends, growth factors & opportunities 4.6.2. Market size and forecast, by region 4.6.3. Market analysis, by country
4.7. Other cancers
4.7.1. Key market trends, growth factors & opportunities 4.7.2. Market size and forecast, by region 4.7.3. Market analysis, by country
CHAPTER 5: CANCER THERAPEUTICS MARKET, BY TOP SELLING DRUGS
5.1. Overview
5.1.1. Market size and forecast
5.2. Revlimid
5.2.1. Market size and forecast, by region 5.2.2. Market analysis, by region
5.3. Avastin
5.3.1. Market size and forecast, by region 5.3.2. Market analysis, by region
5.4. Herceptin
5.4.1. Market size and forecast, by region 5.4.2. Market analysis, by region
5.5. Rituxan
5.5.1. Market size and forecast, by region 5.5.2. Market analysis, by region
5.6. Opdivo
5.6.1. Market size and forecast, by region 5.6.2. Market analysis, by region
5.7. Gleevec
5.7.1. Market size and forecast, by region 5.7.2. Market analysis, by region
5.8. Velcade
5.8.1. Market size and forecast, by region 5.8.2. Market analysis, by region
5.9. Imbruvica
5.9.1. Market size and forecast, by region 5.9.2. Market analysis, by region
5.10. Ibrance
5.10.1. Market size and forecast, by region 5.10.2. Market analysis, by region
5.11. Zytiga
5.11.1. Market size and forecast, by region 5.11.2. Market analysis, by region
5.12. Alimta
5.12.1. Market size and forecast, by region 5.12.2. Market analysis, by region
5.13. Xtandi
5.13.1. Market size and forecast, by region 5.13.2. Market analysis, by region
5.14. Tarceva
5.14.1. Market size and forecast, by region 5.14.2. Market analysis, by region
5.15. Perjeta
5.15.1. Market size and forecast, by region 5.15.2. Market analysis, by region
5.16. Other drugs
5.16.1. Market size and forecast, by region 5.16.2. Market analysis, by region
CHAPTER 6: CANCER THERAPEUTICS MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends, growth factors, and opportunities 6.2.2. North America market size and forecast, by country
6.2.2.1. U.S.
6.2.2.1.1. U.S. market size and forecast, by application
6.2.2.2. Canada
6.2.2.2.1. Canada market size and forecast, by application
6.2.3. North America market size and forecast, by application 6.2.4. North America market size and forecast, by top selling drugs
6.3. Europe
6.3.1. Key market trends, growth factors, and opportunities 6.3.2. Europe Cancer Therapeutics market, by country
6.3.2.1. Germany
6.3.2.1.1. Germany market size and forecast, by application
6.3.2.2. France
6.3.2.2.1. France market size and forecast, by application
6.3.2.3. UK
6.3.2.3.1. UK market size and forecast, by application
6.3.2.4. Italy
6.3.2.4.1. Italy market size and forecast, by application
6.3.2.5. Spain
6.3.2.5.1. Spain market size and forecast, by application
6.3.2.6. Rest of Europe
6.3.2.6.1. Rest of Europe market size and forecast, by application
6.3.3. Europe market size and forecast, by application 6.3.4. Europe market size and forecast, by top selling drugs
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors, and opportunities 6.4.2. Asia-Pacific market size and forecast, by country
6.4.2.1. Japan
6.4.2.1.1. Japan market size and forecast, by application
6.4.2.2. China
6.4.2.2.1. China market size and forecast, by application
6.4.2.3. India
6.4.2.3.1. India market size and forecast, by application
6.4.2.4. Rest of Asia-Pacific
6.4.2.4.1. Rest of Asia-Pacific market size and forecast, by application
6.4.3. Asia-Pacific market size and forecast, by application 6.4.4. Asia-Pacific market size and forecast, by top selling drugs
6.5. LAMEA
6.5.1. Key market trends, growth factors, and opportunities 6.5.2. LAMEA market size and forecast, by country
6.5.2.1. Latin America
6.5.2.1.1. Latin America market size and forecast, by application
6.5.2.2. Middle East
6.5.2.2.1. Middle-East market size and forecast, by application
6.5.2.3. Africa
6.5.2.3.1. Africa market size and forecast, by application
6.5.3. LAMEA market size and forecast, by application 6.5.4. LAMEA market size and forecast, by top selling drugs
CHAPTER 7: COMPANY PROFILES
7.1. AbbVie Inc.
7.1.1. Company overview 7.1.2. Company snapshot 7.1.3. Operating business segments 7.1.4. Business performance 7.1.5. Key strategic moves and developments
7.2. Astellas Pharma Inc.
7.2.1. Company overview 7.2.2. Company snapshot 7.2.3. Operating business segments 7.2.4. Business performance 7.2.5. Key strategic moves and developments
7.3. Bristol Myers Squibb Company
7.3.1. Company overview 7.3.2. Company snapshot 7.3.3. Operating business segments 7.3.4. Business performance 7.3.5. Key strategic moves and developments
7.4. Celgene Corporation
7.4.1. Company overview 7.4.2. Company snapshot 7.4.3. Operating business segments 7.4.4. Business performance
7.5. Eli Lilly and Company
7.5.1. Company overview 7.5.2. Company snapshot 7.5.3. Operating business segments 7.5.4. Business performance 7.5.5. Key strategic moves and developments
7.6. F. Hoffmann-La Roche Ltd.
7.6.1. Company overview 7.6.2. Company snapshot 7.6.3. Operating business segments 7.6.4. Business performance 7.6.5. Key strategic moves and developments
7.7. Johnson & Johnson
7.7.1. Company overview 7.7.2. Company snapshot 7.7.3. Operating business segments 7.7.4. Business performance 7.7.5. Key strategic moves and developments
7.8. Merck & Co., Inc.
7.8.1. Company overview 7.8.2. Company snapshot 7.8.3. Operating business segments 7.8.4. Business performance 7.8.5. Key strategic moves and developments
7.9. Novartis AG
7.9.1. Company overview 7.9.2. Company snapshot 7.9.3. Operating business segments 7.9.4. Business performance 7.9.5. Key strategic moves and developments
7.10. Pfizer Inc.
7.10.1. Company overview 7.10.2. Company snapshot 7.10.3. Operating business segments 7.10.4. Business performance 7.10.5. Key strategic moves and developments
Check Exclusive Discount on this Report @ https://www.kdmarketresearch.com/discount/3201
About Us:
KD Market Research is one of the best market research organization that provides B2B research on the growth opportunities of the industry which is the prime factor of the overall revenue of the organization. We identify the pain points which our client is facing around revenue methods and provide them with a comprehensive database which helps them to make intelligent decisions that could ensure growth to the organization.
Our Services include market intelligence, competitive intelligence, and customized research. These research reports help the organizations to make quick and powerful decisions that make out highest growth in revenue.
Contact us -
KD Market Research
150 State Street, Albany,
New York, USA 12207
Website: www.kdmarketresearch.com
Email id- [email protected]
More - https://kdmarketresearch.blogspot.com/
#Cancer Therapeutics Market size#Cancer Therapeutics Market trends#Cancer Therapeutics Market news#Cancer Therapeutics Market share#Cancer Therapeutics Market Analysis#Cancer Therapeutics MarketForecast
0 notes
Text
Global Biomarker Technologies Market: Industry Analysis and Forecast (2019-2027)
Global Biomarker Technologies Market was valued at US$ 48 Bn in 2019 and is expected to reach US$ 96.51 Bn by 2027, at a CAGR of 9.12 %during the forecast period.
The report includes an analysis of the impact of COVID-19 lockdown on the revenue of market leaders, followers, and disruptors. Since the lockdown was implemented differently in various regions and countries; the impact of the same is also seen differently by regions and segments. The report has covered the current short-term and long-term impact on the market, and it would help the decision-makers to prepare the outline and strategies for companies by region.
Global Biomarker Technologies Market
To know about the Research Methodology :- Request Free Sample Report Global Biomarker Technologies Market Dynamics:
The biomarker is used as a measurable indicator of the severity or presence of some disease state. More generally a biomarker is anything such as gene, biological molecule, or characteristic that can be used as an indicator of a particular disease state or some other physiological state of a living organism. Biomarker technologies are used in Diagnosis, drug development, and formulation for a contact of definite unsafe chemical and prognostic treatments. The capability of biomarkers to diagnose at an early phase is widely used in cancer analysis and treatment. Biomarkers are using as indicators to estimate and compute pathogenic processes, pharmacological reactions, and biological processes.
The biomarker technologies market is expanding globally under the influence of factors such as increasing incidences of various diseases such as cancer, diabetes, cardiovascular and neurological disorders. National Cancer Institute (NCI) revealed that approximately 13,397,159 people were affected by various cancer types in the United States in 2011. According to the International Diabetes Federation (IDF), nearly 382 million people were living with diabetes from all over the world in 2013 and this number is expected to reach nearly 592 million by the end of 2035. China and India represent the first and second positions with a high prevalence of diabetes, 98.4 million and 65.1 million respectively.
The growth of the biomarkers market is highly driven by, increasing cases of diseases especially oncology-based disease, increasing demand for disease-specific biomarkers, growing adoption of personalized medicine. Moreover, an increasing utility of biomarkers for diagnostic purposes because of its accuracy, increasing healthcare expenditure, FDA support for biomarkers development, the government taking initiative in more biomarker research, increasing R&D funding by biotechnology companies and research institute, these factors will help to drive the market of biomarkers at XX% CAGR during the forecast period.
On the other hand, a huge amount of capital investment required for the discovery of biomarkers and their development and high cost of biomarkers, this factor may hamper the growth of the biomarkers market during the forecast period. Global Biomarker Technologies Market Segment Analysis:
Based on product type, the consumables segment accounted for the largest market share of biomarkers in 2019 and is expected to dominate over the others during the forecast period owing to the consumables play a key role in biomarker testing. The consumables market is further segmented into reagents & kits and chromatography columns. In 2019, the reagents & kits segment accounted for the largest share of the consumables market.
By profiling technology, the immunoassay segment accounted for the largest share in 2019 and is expected to drive the market of biomarkers in near future. This segment is further divided into ELISA, protein microarray, and western blot. In 2019, the ELISA segment accounted for the largest share of the immunoassay market. ELISA can quantify levels of multiple proteins and have the potential to accelerate the validation of protein biomarkers simultaneously for clinical use, these factors are helpful for the increasing use of ELISA in conformational studies in biomarker discovery.
The omics technology further divided into proteomics, genetics, and transcriptomics. Omics technology is used in the biomarker discovery technologies market. Biomarkers are used in risk assessment, molecular diagnostic, disease diagnosis, DNA fingerprinting, and other molecular applications. The research area is vaster in omics technology Global Biomarker technologies Market Regional Insights:
North America held the largest share of the biomarker technologies in 2019 attributed to the increasing prevalence of diseases such as cancer, autoimmune diseases, cardiovascular diseases & neurological diseases, increasing expenditure on health, and rising geriatric population, these are the factors responsible for the growth of the biomarker technologies market. Europe had the second-largest market in 2019 and holds a healthy share in the global biomarker technologies market owing to the availability of advanced treatment facilities and established good healthcare infrastructure along with the growing need for efficient and accurate diagnosis and an increasing health expenditure the Asia Pacific is expected to register the highest growth rate from 2019 to 2027 for the biomarker technologies market. The rising incidence of cancer, growing geriatric population, and increasing funds in R&D from private and public organizations for biomarker research, are the factors that will drive the growth of the biomarker technologies market in the Asia Pacific region during the forecast period. Recent Highlights in Global Biomarker Technologies Market
A group of chemists from UNSW Sydney’s Australian Centre for NanoMedicine (ACN) and biologists from UNSW's Lowy Cancer Research Centre have created a new sensor named “Nanopore blockade sensor” that can detect disease biomarkers in very low concentration in a short time.
The objective of the report is to present comprehensive assessment projections with a suitable set of assumptions and methodology. The report helps in understanding Global Biomarker Technologies Market dynamics, structure by identifying and analyzing the market segments and projecting the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, growth strategies, and regional presence. Global Biomarker Technologies Market, Key Highlights:
• Global Biomarker Technologies Market analysis and forecast, in terms of value.
• Comprehensive study and analysis of market drivers, restraints and opportunities influencing the growth of the Global Biomarker Technologies Market
• Global Biomarker Technologies Market segmentation on the basis of type, source, end-user, and region (country-wise) has been provided.
• Global Biomarker Technologies Market strategic analysis with respect to individual growth trends, future prospects along with the contribution of various sub-market stakeholders have been considered under the scope of study.
• Global Biomarker Technologies Market analysis and forecast for five major regions namely North America, Europe, Asia Pacific, the Middle East & Africa (MEA) and Latin America along with country-wise segmentation.
• Profiles of key industry players, their strategic perspective, market positioning and analysis of core competencies are further profiled.
• Competitive developments, investments, strategic expansion and competitive landscape of the key players operating in the Global Biomarker Technologies Market are also profiled.
for more info:https://www.maximizemarketresearch.com/market-report/global-biomarker-technologies-market/31714/
Scope of the Global Biomarker Technologies Market: Inquire before buying
Global Biomarker Technologies Market, by Test Type
• Solid Biopsy • Liquid Biopsy Global Biomarker Technologies Market, by Technology
• ddPCR • NGS • Immunoassay • Mass Spectrometry • DHPLC • Other Technologies Global Biomarker Technologies Market, by Product
• Consumables • Instruments • Services • Software/Informatics Global Biomarker Technologies Market, by Research
• Genomics • Proteomics • Metabolomics o Metabolic Flux o Lipidomics o Others • Other Research Areas Global Biomarker Technologies Market, by Application
• Drug Discovery • Diagnostics • Personalized Medicine Global Biomarker Technologies Market, by Region
• North America • Europe • Asia Pacific • Middle East & Africa • South America Key Players Operating in the Global Biomarker Technologies Market:
• Thermo Fisher Scientific • Bio-Rad Laboratories • Danaher Corporation • Agilent Technologies • Roche • Waters Corporation • Shimadzu Corporation • Illumina, Inc. • F. Hoffmann-La Roche AG • Merck KGAA • PerkinElmer Inc. • Siemens Healthcare • Abbott Laboratories • Qiagen N.V. • Biomérieux SA, • Becton, • Myriad Genetics, • Sysmex Corporation, • Quest Diagnostics • Aushon BioSystem Inc., • Epistem Ltd. • Hologic
For More Information Visit @: This Report Is Submitted By : Maximize Market Research Company Customization of the report: Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.
About Maximize Market Research: Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.
0 notes
Text
DNA sequencing Market is anticipated to reach $25,470 million by 2025
KD Market Insights has published a new report on DNA sequencing Market analysis and forecast 2018-2025. The report comprises of DNA sequencing Market size, Y-o-Y growth analysis, and market dynamics, including growth drivers, restraining factors, opportunities, and trends which are spearheading current nature and future status of the market.
DNA sequencing is a molecular technique that helps determine the nucleotide sequence of DNA (deoxyribonucleic acid), which is the most fundamental level of knowledge of a gene or genome. The global DNA sequencing market accounted for $6,243 million in 2017, and is anticipated to reach $25,470 million by 2025, registering a CAGR of 19.0% from 2017 to 2025. DNA sequencing has revolutionized molecular biology and genomics research. The knowledge of DNA sequences of genes and other parts of the genome of organisms has become essential for life-science research and also in applied fields, such as forensics, cancer diagnostics, and others. Through this method, billions of DNA strands can be sequenced efficiently. DNA sequencing has made it possible to conveniently sequence whole genomes and analyze various DNA-protein interactions. This technique allows the researcher to focus, study, and interpret deep sequence target regions. They are utilized through varied interventions, such as oncology, biomarker studies, drug discovery, understanding reproductive health, and personalized genomics.
Request for Sample @ https://www.kdmarketinsights.com/sample/4326
Technological advancements in sequencing equipment, surge in applications of DNA sequencing, and increase in genome mapping programs drive the global DNA sequencing market. In addition, rise in awareness pertaining to DNA sequencing and increase in investment in research, development, and innovation supplement the market growth. However, lack of skilled professionals, ethical & legal limitations related to DNA sequencing, and standardization concerns in sequencing procedures impede the market growth. Furthermore, use of cloud computing as a potential data management service and the untapped emerging countries offer lucrative opportunities for the market players.
The DNA sequencing market is segmented based on product, application, technology, end user, and geography. Based on product, it is categorized into consumable, instrument, and service. The consumables segment accounted for a dominant share in 2017 and is expected to maintain this trend during the forecast period. This is attributed to the fact that they are widely used throughout the sample preparation process and other pre-requisite steps of DNA sequencing.
Based on application, it is categorized into biomarkers & cancer, diagnostics, reproductive health, personalized medicine, forensics, and other applications. The biomarkers & cancer application was the highest revenue contributor in 2017, while the personalized medicine segment is anticipated to grow at the highest rate. The growth for this segment is due to increase in investment in R&D globally and surge in awareness about DNA sequencing applications in precision medicine. Based on technology, the DNA sequencing technology market is classified into sequencing by synthesis, ion semiconductor sequencing, sequencing by ligation, pyrosequencing, single molecule real-time sequencing, chain termination sequencing, and nanopore sequencing technologies. The sequencing by synthesis technology segment accounted for the highest share in 2017 and is estimated to continue this trend throughout the study period as this technology allows both short and long insert paired end reads for high resolution genome sequencing, structural variation detection, sequence assembly, and others.
Based on region, this market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the highest market share in the DNA sequencing market in 2017 and is expected to maintain its dominance throughout the forecast period. This is primarily attributed to the higher buying power, availability, and applications that favor the utilization of DNA sequencing. There is also an increase in agreements and collaborations between different market players and health centers to promote and utilize DNA sequencing in this region. However, Asia-Pacific is expected to emerge as a lucrative area with maximum growth potential, owing to the improvement in R&D facilities, rise in disposable income, and rapidly development in economic conditions.
Key Benefits for DNA sequencing Market:
- The study provides an in-depth analysis of the global DNA sequencing market and the current trends and future estimations to elucidate the imminent investment pockets. - The report presents quantitative analysis of the market from 2017 to 2025 to enable the stakeholders to capitalize on the prevailing market opportunities. - Extensive analysis of the market based on product assists to understand the trends in the industry. - Key market players and their strategies are thoroughly analyzed to understand the competitive outlook of the industry
Key DNA sequencing Market:
By Product
- Consumable - Instrument - Service
By Application
- Diagnostics - Biomarkers and Cancer - Reproductive Health - Personalized Medicine - Forensics - Other Applications
By Technology
- Sequencing by Synthesis - Ion Semiconductor Sequencing - Sequencing by Ligation - Pyrosequencing - Single Molecule Real-Time Sequencing - Chain Termination Sequencing - Nanopore Sequencing
By End User
- Academic & Government Research Institutes - Pharmaceutical Companies - Biotechnology Companies - Hospitals & Clinics
By Region
North America - U.S. - Canada - Mexico Europe - Germany - France - UK - Italy - Spain - Rest of Europe Asia-Pacific - Japan - China - Australia - India - South Korea - Taiwan - Rest of Asia-Pacific LAMEA - Brazil - Turkey - Saudi Arabia - Rest of LAMEA
List of Key Players Profiled in the Report
- Abbott Laboratories - Agilent Technologies, Inc. - Danaher Corporation (Beckman Coulter, Inc.) - F. Hoffmann-La Roche Ltd - Illumina, Inc - LI-COR Biosciences, Inc. - Pacific Biosciences of California, Inc. - SIEMENS AG; PerkinElmer Inc. - Thermo Fisher Scientific, Inc.
Browse Full Report With TOC@ https://www.kdmarketinsights.com/product/dna-sequencing-market-amrr
Table of Content
CHAPTER 1: INTRODUCTION
1.1. Report description 1.2. Key benefits for stakeholders 1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research 1.4.2. Primary research 1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study 2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope 3.2. Key findings
3.2.1. Top investment pockets
3.3. Top winning strategies 3.4. Market share analysis
3.4.1. Overview
3.5. Patents analysis
3.5.1. Patent analysis, by region 3.5.2. Patent analysis, by year
3.6. Porters five forces analysis 3.7. Market dynamics
3.7.1. Drivers
3.7.1.1. Technological advancements in DNA sequencing 3.7.1.2. Surge in applications of DNA sequencing 3.7.1.3. Increase in partnerships and collaborations 3.7.1.4. Increase in genome mapping programs
3.7.2. Restraints
3.7.2.1. Standardization concerns over DNA sequencing-based diagnostics 3.7.2.2. Dearth of skilled professionals 3.7.2.3. Ethical and legal limitations
3.7.3. Opportunities
3.7.3.1. Lucrative opportunities in emerging markets 3.7.3.2. Cloud computing as a potential data management service
3.7.4. Impact analyses
CHAPTER 4: DNA SEQUENCING MARKET, BY PRODUCT
4.1. Overview
4.1.1. Market size and forecast
4.2. Consumables
4.2.1. Key market trends, growth factors, and opportunities 4.2.2. Market size and forecast, by region 4.2.3. Market analysis, by country
4.3. Instruments
4.3.1. Key market trends, growth factors, and opportunities 4.3.2. Market size and forecast, by region 4.3.3. Market analysis, by country
4.4. Services
4.4.1. Key market trends, growth factors, and opportunities 4.4.2. Market size and forecast, by region 4.4.3. Market analysis, by country
CHAPTER 5: DNA SEQUENCING MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Biomarker & cancer
5.2.1. Market size and forecast, by region 5.2.2. Market share analysis
5.3. Diagnostics
5.3.1. Market size and forecast, by region 5.3.2. Market share analysis, by country
5.4. Reproductive health
5.4.1. Market size and forecast, by region 5.4.2. Market share analysis, by country
5.5. Personalized medicine
5.5.1. Market size and forecast, by region 5.5.2. Market share analysis, by country
5.6. Forensics
5.6.1. Market size and forecast, by region 5.6.2. Market share analysis
5.7. Others
5.7.1. Market size and forecast, by region 5.7.2. Market share analysis
CHAPTER 6: DNA SEQUENCING MARKET, BY TECHNOLOGY
6.1. Overview
6.1.1. Market size and forecast
6.2. Sequencing by synthesis
6.2.1. Market size and forecast, by region 6.2.2. Market analysis, by country
6.3. Ion semiconductor sequencing
6.3.1. Market size and forecast, by region 6.3.2. Market share analysis, by country
6.4. Sequencing by ligation
6.4.1. Market size and forecast, by region 6.4.2. Market share analysis, by country
6.5. Pyrosequencing
6.5.1. Market size and forecast, by region 6.5.2. Market share analysis, by country
6.6. Single-molecule real-time sequencing
6.6.1. Market size and forecast, by region 6.6.2. Market share analysis, by country
6.7. Chain termination technology
6.7.1. Market size and forecast, by region 6.7.2. Market share analysis, by country
6.8. Nanopore sequencing
6.8.1. Market size and forecast, by region 6.8.2. Market share analysis, by country
CHAPTER 7: DNA SEQUENCING MARKET, BY END USER
7.1. Overview
7.1.1. Market size and forecast
7.2. Academic & government research institute
7.2.1. Market size and forecast, by region 7.2.2. Market share analysis, by country
7.3. Pharmaceutical companies
7.3.1. Market size and forecast, by region 7.3.2. Market share analysis, by country
7.4. Biotechnology companies
7.4.1. Market size and forecast, by region 7.4.2. Market share analysis
7.5. Hospital & clinics
7.5.1. Market size and forecast, by region 7.5.2. Market share analysis
Continue….
Check for Discount @ https://www.kdmarketinsights.com/discount/4326
About KD Market Insights
KD Market Insights offers a comprehensive database of syndicated research studies, customized reports, and consulting services. These reports are created to help in making smart, instant and crucial decisions based on extensive and in-depth quantitative information, supported by extensive analysis and industry insights.
Our dedicated in-house team ensures the reports satisfy the requirement of the client. We aim at providing value service to our clients. Our reports are backed by extensive industry coverage and is made sure to give importance to the specific needs of our clients. The main idea is to enable our clients to make an informed decision, by keeping them and ourselves up to date with the latest trends in the market.
Contact Us
KD Market Insights
150 State Street, Albany,
New York, USA 12207
+1 (518) 300-1215
Email: [email protected]
Website: www.kdmarketinsights.com
Read More News: http://kdmarketinsights.blogspot.com/
https://marketreserachtab.blogspot.com/
#DNA sequencing Market#DNA sequencing Market Size#DNA sequencing Market Share#DNA sequencing Market Trends
0 notes
Text
Diagnostic Imaging Market Global Trends, Market Share, Industry Size, Growth, Opportunities, and Market Forecast 2019 to 2026
Global Diagnostic Imaging Market to value over US $ 33 billion and grow at a CAGR of over 5% during the forecast period of 2019 to 2026.
With rising consciousness about the benefits of early-stage diagnosis which has resulted in a surge for the demand for diagnostic services.This is regarded as an essential and primary growth inducer for the global medical imaging market. Factors such as rising geriatric population and access to cost-effective medical imaging systems are also making a positive impact on the market. Technological improvements are playing an important role, as it is central to the particular healthcare vertical. Hence, market players are consistently exploring and innovating to develop more efficient medical imaging devices.
With the rise in geriatric population, the prevalence of chronic diseases is also on the rise. This is due to the erratic sedentary lifestyle and poor dietary patterns. Cardiovascular and cancerous ailments cause major casualties and are proven to be fatal. Early diagnosis can greatly increase patient survival rate, which is why developing countries are taking initiatives to spread awareness about medical imaging and diagnostics.
Demand for diagnostic services is anticipated to grow during the forecast period due to a rise in the number of patients gaining access to medical facilities. Medical imaging will remain a pivotal area of focus for healthcare technology companies.The market is likely to witness new entrants who will explore and fund unique and novel imaging solutions.The emphasis that is being placed on the technical aspects of medical imaging has led to increased processing speed, integrating 3D and 4D imaging technology and automation among others. Such technological enhancements are favoring the adoption of medical imaging in hospitals and diagnostic centers.
Globally, North America and Europe will collectively account for major market share in the diagnostic imaging systems market. This can be mainly attributed to the presence of established players, increasing adoption of telemedicine, and the rise in the prevalence of chronic diseases in these regions.
The governments across the globe are running awareness programs to educate people regarding early diagnosis of chronic diseases. Such initiatives make patients aware of the early diagnosis among healthcare providers and consumers. Diagnostic imaging has helped doctors to detect diseases in the beginning, thereby improving patient survival rates. Diagnostic imaging systems improve healthcare quality and reduce healthcare costs by shortening recovery time and avoiding unnecessary invasive procedures. Such factors are playing a pivotal role in the growth of the diagnostic imaging systems market.
The market is characterized by developments and strategies by main firms. For instance, in 2019, the U.S. Food and Drug Administration (USFDA) approved Siemens Healthineers’ MAGNETOM Lumina 3 Tesla MRI scanner. The system features BioMatrix patient personalization technology, which significantly improves productivity while reducing scan time. Furthermore, in 2018, Carestream Health Inc. received the USFDA 510(k) clearance for its OnSight 3D Extremity System. This imaging system uses cone beam CT technology to capture weight-bearing and other types of extremity exams. These developments fuel the market and advance it globally, thus helping it grow extensively.
Major firms in the diagnostic imaging systems market are Konica Minolta Inc., Dornier MedTech GmbH, SternMed GmbH, MinFound Medical Systems Co. Ltd., DRGEM CO. LTD., SonoScape Medical Corporation, Analogic Corporation, and Fonar Corporation
Request a Sample Report @ https://www.futurewiseresearch.com/request-sample.aspx?id=2330&page=requestsample
Market Segmentation:
By Product
● MRI Systems
o By Architecture
● Closed MRI Systems
● Open MRI Systems
o By Field Strength
● High and Very-High Field MRI Systems
● Low-To-Mid-Field Systems
● Ultra-High-Field Systems
● Ultrasound Imaging Systems
o By Technology
● 2D Ultrasound
● 3D and 4D Ultrasound
● Doppler Ultrasound
o By Portability
● Trolley/Cart-Based Ultrasound Systems
● Compact/Portable Ultrasound Systems
● 6.4 CT Scanners
o By Type
● Conventional CT Scanners
■ High-Slice CT Scanners
■ Mid-Slice CT Scanners
■ Low-Slice CT Scanners
■ Cone Beam CT Scanners
● Nuclear Imaging Systems
o Spect Systems
■ Hybrid Spect System
■ Standalone Spect Systems
o Hybrid PET Systems
● X-Ray Imaging Systems
o By Type
■ Digital X-Ray Imaging Systems
■ Direct Radiography Systems
■ Computed Radiography Systems
■ Analog X-Ray Imaging Systems
o By Portability
■ Stationary Systems
■ Portable Systems
■ Mammography Systems
By Application
● X-Ray Imaging Systems
o General Radiography
o Dental
o Fluoroscopy
● MRI Systems
o Brain & Neurological MRI
o Spine & Musculoskeletal MRI
o Vascular MRI
o Pelvic & Abdominal MRI
o Breast MRI
● Ultrasound Systems
o Radiology/General Imaging
o Obstetrics/Gynecology (OB/GYN)
o Cardiology
o Vascular
o Urology
o Other Applications
● CT Scanners
o Cardiology
o Oncology
o Neurology
o Other Applications
● Nuclear Imaging Systems
o Cardiology
o Oncology
o Neurology
o Other Applications
● Mammography Systems
By End-User
● Hospitals
● Diagnostic Imaging Centers
● Other End Users
By Region
● Europe
● North America
● APAC
● Latin America
● Rest of the World
Purchase a Copy & Ask For Discount: https://www.futurewiseresearch.com/request-sample.aspx?id=2330&page=askfordiscount
Competitive Landscape:
● Tier 1 players- established companies in the market with a major market share
● Tier 2 players
● Emerging players which are growing rapidly
● New Entrants
FutureWise Takeaways:
● Growth prospects
● SWOT analysis
● Key trends
● Key data points affecting market growth
Objectives of the Study:
● To provide an exhaustive analysis on the global diagnostic imaging market by product, by application, by end-user and by region
● To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
● To evaluate and forecast micro-markets and the overall market
● To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the rest of the world
● To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions
● Profiling of companies to evaluate their market shares, strategies, financials and core competencies
Table of Contents
1 Introduction
1.1 Objectives of the Study 1.2 Market Definition 1.3 Markets Scope 1.3.1 Markets Covered 1.3.2 Years Considered for the Study 1.4 Currency 1.5 Limitations 1.6 Stakeholders
2 Research Methodology 2.1 Research Methodology Steps 2.2 Secondary and Primary Research Methodology 2.2.1 Secondary Research 2.2.1.1 Key Data From Secondary Sources 2.3 Regulatory Landscape 2.3.1 Primary Research 2.3.1.1 Key Data From Primary Sources 2.4 Market Size Estimation 2.4.1 Product-Based Market Estimation 2.4.2 Primary Research Validation 2.5 Market Breakdown and Data Triangulation 2.6 Research Assumptions and Limitations 2.6.1 Assumptions for the Study 2.6.2 Limitations
3 Executive Summary
4 Premium Insights 4.1 Diagnostic Imaging: Market Overview 4.2 Diagnostic Imaging Market, By Product, 2019 vs 2024 (USD Million) 4.3 Geographic Analysis: APAC Diagnostic Imaging Market Share, By Product and Country, 2019 4.4 End User Analysis: Market Share, 2019 vs 2024 4.5 Geographic Snapshot of the Diagnostic Imaging Market
5 Market Overview 5.1 Introduction 5.2 Market Dynamics 5.2.1 Drivers 5.2.1.1 Rapidly Growing Geriatric Population and the Subsequent Increase in the Prevalence of Associated Diseases 5.2.1.2 Increasing Demand for Early Diagnosis and Widening Scope of Clinical Applications 5.2.1.3 Technological Advancements in Diagnostic Imaging Modalities 5.2.1.4 Increasing Investments, Funds, and Grants By Public-Private Organizations 5.2.2 Restraints 5.2.2.1 High Cost of Diagnostic Imaging Systems 5.2.2.2 Technological Limitations Associated With Standalone Systems 5.2.2.3 Declining Reimbursements and Increasing Regulatory Burden in the US 5.2.2.4 Shortage of Helium 5.2.3 Opportunities 5.2.3.1 High Growth Opportunities in Emerging Countries 5.2.3.2 Adoption of Artificial Intelligence and Analytics in Diagnostic Imaging 5.2.3.3 Use of Blockchain in Diagnostic Imaging 5.2.3.4 Increasing Adoption of Teleradiology 5.2.3.5 Contract-Based Radiology Solutions and Mobile Solutions 5.2.4 Challenges 5.2.4.1 Hospital Budget Cuts 5.2.4.2 Increasing Adoption of Refurbished Diagnostic Imaging Systems 5.2.4.3 Dearth of Trained Professionals 5.3 Trends & Burning Issues 5.3.1 Increasing Adoption of Hybrid Diagnostic Imaging Modalities 5.3.2 Overutilization of Diagnostic Imaging Services Around the World 5.4 Pricing Analysis
6 Diagnostic Imaging Market, By Product 6.1 Introduction 6.2 MRI Systems 6.2.1 MRI Systems Market, By Architecture 6.2.1.1 Closed MRI Systems 6.2.1.1.1 Closed MRI Systems are Widely Adopted Across the Globe 6.2.1.2 Open MRI Systems 6.2.1.2.1 Open MRI Can Reduce Anxiety in Claustrophobic Individuals 6.2.2 MRI Systems Market, By Field Strength 6.2.2.1 High and Very-High Field MRI Systems 6.2.2.1.1 High and Very-High Field MRI Systems Dominate the Global MRI Systems Market 6.2.2.2 Low-To-Mid-Field Systems 6.2.2.2.1 Technological Limitations have Reduced the Adoption of Low-To-Mid-Field MRI Systems 6.2.2.3 Ultra-High-Field Systems 6.2.2.3.1 Innovation and Advancements in Applications Have Supported the Demand for Ultra-High-Field Systems 6.3 Ultrasound Imaging Systems 6.3.1 Ultrasound Systems Market, By Technology 6.3.1.1 2D Ultrasound 6.3.1.1.1 2D Ultrasound Dominates the Global Ultrasound Systems Market 6.3.1.2 3D and 4D Ultrasound 6.3.1.2.1 Technological Advancements and Potential are Driving the Demand for 3D & 4D Ultrasound 6.3.1.3 Doppler Ultrasound 6.3.1.3.1 While Noninvasive, Doppler Imaging Can Heat Tissues Being Scanned 6.3.2 Ultrasound Systems Market, By Portability 6.3.2.1 Trolley/Cart-Based Ultrasound Systems 6.3.2.1.1 Wide Applications and Technological Advancements in Trolley/Cart-Based Systems are Driving Market Growth 6.3.2.2 Compact/Portable Ultrasound Systems 6.3.2.2.1 High Portability and Ease of Use is Contributing to the Demand for Compact Systems 6.4 CT Scanners 6.4.1 CT Scanners Market, By Type 6.4.1.1 Conventional CT Scanners 6.4.1.1.1 Conventional CT Scanners Market, By Type 6.4.1.1.1.1 High-Slice CT Scanners 6.4.1.1.1.1.1 High Imaging Resolution and Wide Applications of High-Slice Scanners have Made Them Popular Among End Users 6.4.1.1.1.2 Mid-Slice CT Scanners 6.4.1.1.1.2.1 Affordability of Mid-Slice CT has Driven Its Adoption in Emerging Markets 6.4.1.1.1.3 Low-Slice CT Scanners 6.4.1.1.1.3.1 Low-Slice CT Scanners are Being Replaced With Mid-Slice CT Systems 6.4.1.2 Cone Beam CT Scanners 6.4.1.2.1 Lower Radiation Exposure and Increasing Applications in Dental and Limb Scanning have Driven CBCT Adoption 6.5 Nuclear Imaging Systems 6.5.1 Spect Systems 6.5.1.1 Hybrid Spect Systems 6.5.1.1.1 High Cost and Shortage of Technetium-99m Have Hindered Market Growth 6.5.1.2 Standalone Spect Systems 6.5.1.2.1 Low Cost, Technological Advancements, and Long Radiotracer Half-Life Have All Contributed to Market Growth 6.5.2 Hybrid PET Systems 6.5.2.1 Hybrid PET Systems Hold Greater Prospects of Dominating the Nuclear Imaging Systems Market in the Near Future 6.6 X-Ray Imaging Systems 6.6.1 X-Ray Imaging Systems Market, By Type 6.6.1.1 Digital X-Ray Imaging Systems 6.6.1.1.1 Direct Radiography Systems 6.6.1.1.1.1 High Throughput Capabilities and Quick Operations Have Propelled the Demand for DR Systems 6.6.1.1.2 Computed Radiography Systems 6.6.1.1.2.1 CR Technology is Rapidly Replacing Analog Systems Acting in the Emerging Economies 6.6.1.2 Analog X-Ray Imaging Systems 6.6.1.2.1 Higher Risk of Radiation Exposure and Technological Limitations Impede Market Growth of Analog Systems 6.6.2 X-Ray Imaging Systems Market, By Portability 6.6.2.1 Stationary Systems 6.6.2.1.1 Greater Integration of Configurations Makes Stationary X-Ray Systems Preferable in A Diagnostic Clinic 6.6.2.2 Portable Systems 6.6.2.2.1 Portable X-Ray Systems Show High Adoption in Trauma Care and Emergency Departments 6.7 Mammography Systems 6.7.1 Mammography Systems Segment to Grow at the Highest CAGR
7 Diagnostic Imaging Market, By Application 7.1 Introduction 7.2 X-Ray Imaging Systems 7.2.1 General Radiography 7.2.1.1 General Radiography Applications Account for the Largest Share of the X-Ray Imaging Systems Market 7.2.2 Dental 7.2.2.1 High Prevalence of Dental Disorders to Drive the Growth of This Application Segment 7.2.3 Fluoroscopy 7.2.3.1 Product Launches and Approvals of Fluoroscopy Systems to Support the Growth of This Application Segment 7.3 MRI Systems 7.3.1 Brain & Neurological MRI 7.3.1.1 Brain & Neurological MRI Segment Dominates the MRI Systems Market Due to the Growing Incidence of Neurodegenerative Diseases and Brain Injuries 7.3.2 Spine & Musculoskeletal MRI 7.3.2.1 MRI is the Most-Preferred Imaging Method for the Diagnosis and Prognosis of MSK Disorders and Spinal Injuries 7.3.3 Vascular MRI 7.3.3.1 Rising Incidence of Vascular Disorders to Drive the Market for This Application Segment 7.3.4 Pelvic & Abdominal MRI 7.3.4.1 Increasing Incidence of Pelvic & Abdominal Diseases to Support Market Growth 7.3.5 Breast MRI 7.3.5.1 Rising Prevalence of Breast Cancer and Increasing Awareness About Early Breast Cancer Screening—Key Drivers for the Breast MRI Market 7.3.6 Cardiac MRI 7.3.6.1 Rising Incidence of Cvd and Technological Advancements in Cardiac MRI are the Key Factors Supporting the Growth of This Application Segment 7.4 Ultrasound Systems 7.4.1 Radiology/General Imaging 7.4.1.1 Radiology/General Imaging is the Largest Application Segment of the Ultrasound Market 7.4.2 Obstetrics/Gynecology (OB/GYN) 7.4.2.1 Increasing Demand for Minimally Invasive Techniques in Gynecological Diagnostic Procedures to Support Market Growth 7.4.3 Cardiology 7.4.3.1 Cardiology is One of the Largest and Most-Widely Used Ultrasound Application Segments 7.4.4 Vascular 7.4.4.1 Vascular Ultrasound is One of the Fastest-Growing Application Segments for Ultrasound Technologies Across Major Markets 7.4.5 Urology 7.4.5.1 Rising Incidence of Prostate Disorders & Kidney Stones and Technological Innovations in the Field of Urological Ultrasound to Drive the Market for This Application Segment 7.4.6 Other Applications 7.5 CT Scanners 7.5.1 Cardiology 7.5.1.1 Cardiac CT is One of the Largest and Most-Widely Used CT Application Segments Across the Globe 7.5.2 Oncology 7.5.2.1 Rising Incidence of Cancer and Technological Advancements in CT Scanners to Support Market Growth 7.5.3 Neurology 7.5.3.1 Increasing Adoption of CT Scanners for Diagnosing Various Neurological Conditions to Drive Market Growth 7.5.4 Other Applications 7.6 Nuclear Imaging Systems 7.6.1 Cardiology 7.6.1.1 High Prevalence of CVD is the Major Factor Driving the Growth of This Segment 7.6.2 Oncology 7.6.2.1 Nuclear Imaging Systems Can Distinguish Between Benign and Malignant Tumors, Which Help Physicians in Precise Diagnosis and Decision Making 7.6.3 Neurology 7.6.3.1 Increasing Demand of Nuclear Imaging Procedures for Diagnosing Neurological Disorders is Supporting the Growth of This Segment 7.6.4 Other Applications 7.7 Mammography Systems
8 Diagnostic Imaging Market, By End User 8.1 Introduction 8.2 Hospitals 8.2.1 Large Hospitals Have Been Early Adopters of Diagnostic Imaging Systems 8.3 Diagnostic Imaging Centers 8.3.1 Increasing Number of Private Imaging Centers is Contributing to Market Growth 8.4 Other End Users
9 Diagnostic Imaging Market, By Region 9.1 Introduction 9.2 North America 9.2.1 US 9.2.1.1 US Dominated the North American Market in 2018 9.2.2 Canada 9.2.2.1 Dearth of Radiologists and Long Wait Time for Scans are the Major Challenges in the Canadian Market 9.3 Europe 9.3.1 Germany 9.3.1.1 Germany Accounted for the Largest Share of the European Market 9.3.2 UK 9.3.2.1 Government Initiatives to Support Market Growth in the UK 9.3.3 France 9.3.3.1 Uncertainties With Regard to the Pricing Strategy of Diagnostic Companies to Limit Market Growth in France to A Certain Extent 9.3.4 RoE 9.4 Asia Pacific 9.4.1 China 9.4.1.1 Government Initiatives in the Form of Healthcare Reforms and Investments and the Rapidly Growing Aging Population to Drive the Growth of the Market in China 9.4.2 Japan 9.4.2.1 Fast Adoption of Advanced Technologies as Well as Investments and Innovations From Key Market Players are Key Growth Drivers 9.4.3 India 9.4.3.1 Uncertainties in Healthcare Policies Might Restrict the Growth of the Market in India in the Coming Years 9.4.4 RoAPAC 9.5 Rest of the World 9.5.1 Latin America 9.5.2 Middle East & Africa
10 Competitive Landscape 10.1 Introduction 10.2 Market Share Analysis, By Key Players 10.2.1 Diagnostic Imaging Market 10.2.2 X-Ray Imaging Systems Market 10.2.3 MRI Systems Market 10.2.4 CT Scanners Market 10.2.5 Ultrasound Imaging Systems Market 10.2.6 Nuclear Imaging Systems Market 10.2.7 Mammography Systems Market 10.3 Competitive Situation and Trends 10.4 Competitive Leadership Mapping 10.5 Vendor Inclusion Criteria 10.5.1 Vendor Dive 10.5.2 Innovators 10.5.3 Dynamic Differentiators 10.5.4 Emerging Players 10.5.5 Visionary Leaders 10.5.6 Progressive Companies 10.5.7 Starting Blocks 10.5.8 Responsive Companies 10.5.9 Dynamic Companies
11 Company Profiles (Business Overview, Products Offered, Recent Developments, and FutureWise View)* 11.1 GE Healthcare (General Electric Company) 11.2 Koninklijke Philips N.V. 11.3 Siemens Healthineers (Subsidiary of Siemens Group) 11.4 Canon Inc. 11.5 Hitachi, Ltd. 11.6 Shimadzu Corporation 11.7 Carestream Health 11.8 Esaote SPA 11.9 FUJIFILM Holdings Corporation 11.10 Samsung Electronics Co., Ltd. 11.11 Agfa–Gevaert N.V. 11.12 Hologic, Inc. 11.13 CurveBeam LLC 11.14 Planmed Oy 11.15 Mindray Medical International Limited (A Subsidiary of Excelsior Union, Ltd.)
*Details on Business Overview, Products Offered, Recent Developments, and FutureWise View Might Not Be Captured in Case of Unlisted Companies.
Inquire further details about this report at: [email protected]
About FutureWise Research:
We specialise in high-growth niche markets, assuring flexibility, agility and customised solutions for our clients. Through in-depth market insights and consultancy, we present our clients with the tools they need to be at the forefront of their industry – a position secured for far more than the near future.
Contact Us:
Company Name: FutureWise Research Contact Person: Vinay Thaploo Email: [email protected] Phone: +44 141 628 9353 / +1 970 279 4295 City: Leeds Country: United Kingdom Website: www.futurewiseresearch.com
#Diagnostic Imaging Market Share#Diagnostic Imaging Market Size#Diagnostic Imaging Market Trend#Diagnostic Imaging Market Forecast#Diagnostic Imaging Market
0 notes
Text
The Global Market Survey On Cancer Gene Therapy Market Share, Revenue, Demand and Forecast to 2025
The Global Market Survey On Cancer Gene Therapy Market. The Gene Therapy Market Is Forecasted To Jump XX USD Mn By 2024
· The global cancer gene therapy market is segmented on the basis of type, therapy and end-users
· The global cancer gene therapy market is expected to reach XX USD Mn by 2024 with a growing CAGR of XX% from 2018 to 2024
· The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
Request Sample Report: https://bit.ly/2INre91
Cancer gene therapy is a process that treats cancers by inserting therapeutic DNA into the patient. Cancer gene therapy is gaining popularity as a result of its success rate in preclinical and clinical trial stages. The most common technique for cancer gene therapy involves replacing a mutated gene that is causing cancer with a healthy copy of the gene.
Globally, rising cancer prevalence will increase demand for gene therapy as the effective personalized treatment choice. Various factors, such as the increase in the prevalence of cancer, increase in funding from various government and non-government organizations, ethical acceptance of gene therapy for treatment of diseases and growing popularity of DNA vaccines is driving the global cancer gene therapy market. However, less awareness and high cost involved in treatment, lack of reimbursement policies for advanced gene therapy methods are restraining the growth of the global market for cancer gene therapy.
The global cancer gene therapy market is divided into following categories-
1. Type
· Gene Induced Immunotherapy
o Tumour Antigen Gene Delivery
o Cytokine Gene Delivery
· Oncolytic Virotherapy
o Adenoviruses
o Adeno Associated Virus
o Lentiviruses
o Alpha Virus
o Retrovirus
o Herpes Simplex Virus
o Vaccinia virus
o Simian Virus
· Gene Transfer/ Gene Replacement
· Electroporation
· Magnetofection
· Naked / Plasmid Vectors
· Gene Gun
· Sonoporation
2. Therapy
· Retroviral Therapy
· Adenoviral Therapy
3. End-users
· Hospitals
· Oncology institutes
· Biotechnological companies
· Clinical Research Labs
And geographically, the cancer gene therapy is segmented into North America, Europe, Latin America, Asia- Pacific and the Middle East and Africa.
North America leads the global cancer gene therapy market owing to the large pool of aging population and advancements in technology high investments in R & D activities along with the government support will boost industry demand.
The U.K. market is anticipated to grow rapidly due to the rising occurrence of cancer along with the increase in acceptance of gene technology.
Asia-Pacific is expected to witness high growth in cancer gene therapy market, due to increase in government initiatives, rising economy, and improvement in healthcare infrastructure in the region.
Some of the major companies operating in the global cancer gene therapy market are Urigen Pharmaceuticals Inc. (U.S), GenVec.Inc (U.S), Oxford BioMedica (U.K), Vical (U.S), ANI Pharmaceuticals, Inc. (U.S), and Genzyme Corporation (U.S). Novartis AG (Switzerland), and Cell Medica (U.K.). Some of the market development include Novartis receiving U.S. FDA Oncologic Drugs Advisory Committee (ODAC) recommended approval of CTL019, in 2017, an investigational chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of relapsed or refractory pediatric and young adult patients with B-cell acute lymphoblastic leukemia.
Major industry participants adopting various strategies to retaining their market positions such as the development of advanced technologies, maintaining a strong intellectual property, strategic collaborations, and joint ventures adopted by in the global cancer gene therapy. The players are constantly engaged in R&D in order to develop novel methods to treat various life-threatening diseases. Increased in the adoption of emerging genomic technologies such as Next Generation Sequencing (NGS) and high-density microarray coupled with favorable government initiatives will fuel global cancer gene therapy market.
Key Questions Answered
· What is the current and future cancer gene therapy market outlook worldwide? What trends are affecting the global market?
· What is the competitive landscape and market share of major players in the cancer gene therapy globally?
· What are the key, high growth markets that cancer gene therapy manufacturers should expand into? Which market segments are growing the fastest?
· What are the unmet needs with the cancer gene therapy currently on the market? How will emerging technologies fulfil these unmet needs?
· What is physician perception and market outlook of cancer gene therapy?
· What are the challenges and barriers that have hindered widespread adoption of cancer gene therapy?
Reasons to buy cancer gene therapy market Report:
· Global, regional and country-level analysis and forecasts of the study market; providing Insights on the geographical areas in which this industry is prospering
· Segment-level analysis on basis of product type, application, colour along with market size forecasts and y-o-y estimations to detect key areas of industry growth in detail
· Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
· Study of macro and micro environmental factors that affect the market presented in an extensive strategic analyses section containing PESTLE and Porter’s Five Forces Analyses
· A comprehensive listing of key market players along with company overview, product portfolios, key financial information (subjected to availability), SWOT analysis and Analyst overview to study and sustain the market environment
· Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
· Expertly devised Market Outlook along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
For More Information:
https://bit.ly/2N5JYRQ
0 notes
Text
Global Sterile Injectables Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023
Global Sterile Injectables Market: By Molecule Type (Large Molecules, Small Molecules), Drug Type (Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Blood Factors, Vaccines, Immunoglobulins, Peptide Antibiotics, and Others), Disease Indication (Cancer, Diabetes, Cardiovascular Diseases, Musculoskeletal, CNS, Infections, and Others), Route of Administration (Intravenous (IV), Intramuscular (IM), Subcutaneous (SC), and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and Geography – Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023
Sterile Injectables Market Report Description:
Sterile Injectables market report gives a comprehensive outlook on sterile injectable across the globe with special emphasis on key regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (MEA). This report on the sterile injectable market gives historical, current, and future market sizes (US$ Mn) of drug molecules, drug types, disease application, route of administration, end users, and geographic regions. This report studies sterile injectable market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, the sterile injectable market report includes drug pipeline analysis, regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analysed sterile injectable market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the sterile injectable market report include suppliers, manufacturers, marketers, policymakers engaged in manufacturing and supply of sterile injectables.
A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-sterile-injectables-market/#ulp-4H8Z4LpNMLEuOnnx
Sterile Injectables Market:
The sterile injectable market estimated to be valued US$ 361 Bn in 2016 and poised to grow at CAGR 7.3%. The market for sterile injectable projected to reach US$ 552 Bn by 2023.
Do the burgeoning product pipelines and drug patent expiries have a positive impact on the market?
The rising shift of pharmaceutical and biotechnology firms towards the development of medications for chronic diseases such as cancer, diabetes, and cardiovascular and among others have created ample growth opportunities for players in the market. Moreover, biologic have become a larger part of product pipelines of several drug developers, which could affect market growth positively over the forecast period. For instance, there are around 2,500 injectable products are in the developmental stage. Moreover, rising product patent expiries of several blockbusters in recent times expected to propel market growth over the forecast period. For instance, in 2015, Teva Pharmaceutical Industries Ltd. lost the patent for its top-selling multiple sclerosis drug Copaxone.
How operational and installation cost effects the sterile injectable market?
Several industry experts noted that the cost of establishing sterile injectable plants is significantly higher viz-a-viz non-sterile manufacturing plants owing to stringent aseptic requirements and complex manufacturing process; this has led to the consolidation of the industry by backward and forward integration. Moreover, competition from low-cost manufacturers, value chain integration coupled with high entry barrier for new players in the sterile injectable market expect impact market growth negatively over the forecast period.
North America accounts for larger market revenue share in global sterile injectable market
North America leads the global sterile injectable market in terms of revenue in 2016. Regions such as Asia Pacific and Europe presented better growth opportunities for the market players owing to conducive business policies and increased local production generic injectable. For instance, in 2013, Mylan Inc. completed the acquisition of the Agila injectables businesses from Strides Arcolab Limited.
To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-sterile-injectables-market/#ulp-c654SbFYO64MsOhu
Competition Assessment
Key players profiled in the global sterile injectable market include:
· AbbVie Inc. (U.S)
· Amgen Inc. (U.S)
· AstraZeneca plc (U.K)
· Baxter International Inc. (U.S)
· Eli Lilly and Company (U.S)
· GILEAD SCIENCES, INC. (U.S)
· GlaxoSmithKline plc. (U.K)
· Johnson & Johnson Services, Inc. (U.S)
· Merck & Co., Inc. (U.S)
· Novo Nordisk A/S (Denmark)
· Novartis AG (Switzerland)
· Pfizer Inc. (U.S)
· F. Hoffmann-La Roche AG (Switzerland)
· Sanofi (France)
Market players are focusing on mergers and acquisitions to improve their market position in sterile injectable market. For instance, in 2016, Baxter International Inc. acquired Claris Injectables Limited, a wholly owned subsidiary of Claris Lifesciences Limited, for total consideration of approximately $625mn. In 2015 Pfizer Inc. acquired Hospira, Inc., world’s leading provider of injectable and infusion technologies.
Key Findings of the Report:
· Sterile injectable market expanding at 7.3% CAGR over 2017 to 2023 to reach market value of US$ 552 Bn by 2023
· Based on molecule type large molecules accounted for larger market share in 2016
· Oncology segment expected to be most lucrative market in global sterile injectable market
· Hospital pharmacies are prime channel for sterile drug distribution across the globe
· Players focusing on expanding geographic presence to garner market opportunities in developing economies
Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/global-sterile-injectables-market/#ulp-14mlyhjMGhVjZqa3
Key Features of the Report:
· The report provides granular level information about the market size, regional market share, historic market (2012-2016) and forecast (2017-2023)
· The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
· The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
· The report tracks recent innovations, key developments and startup’s details that are actively working in the market
· The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
· The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Detailed Segmentation
By Molecule Type
· Large Molecules
· Small Molecules
Drug Type
· Monoclonal Antibodies
· Cytokines
· Insulin
· Peptide Hormones
· Blood Factors
· Vaccines
· Immunoglobulins
· Peptide Antibiotics
· Others
Disease Indication
· Cancer
· Diabetes
· Cardiovascular Diseases
· Musculoskeletal
· CNS
· Infections
· Others
Route of Administration
· Intravenous (IV)
· Intramuscular (IM)
· Subcutaneous (SC)
· Others
Distribution Channel
· Hospital Pharmacies
· Retail Pharmacies
· Online Pharmacies
Geography
· North America
o U.S.
o Canada
· Europe
o Germany
o France
o U.K.
o Italy
o Spain
o Russia
o Poland
o Rest of Europe
· Asia-Pacific
o Japan
o China
o India
o Australia & New Zealand
o ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
o South Korea
o Rest of Asia-Pacific
· Latin America
o Brazil
o Mexico
o Argentina
o Venezuela
o Rest of Latin America
· Middle East and Africa (MEA)
o Gulf Cooperation Council (GCC) Countries
o Israel
o South Africa
o Rest of MEA
Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/global-sterile-injectables-market/
About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.
Contact to Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: [email protected]
Toll Free (US): +1-866-598-1553
Website @ https://www.precisionbusinessinsights.com
0 notes
Text
Central Venous Catheter Market Analysis (2020-2027) #Marketresearch
Central venous catheterization is applicable in various therapeutic areas such as cardiology, oncology, and nephrology. Central venous catheterization is used in cardiovascular procedures for drug administration, chemotherapy administration in cancer patients, and hemodialysis of patients with chronic kidney diseases. High prevalence of chronic diseases such as cancer, cardiovascular diseases, and chronic kidney disease (CKD) is propelling demand for central venous catheterization, which is expected to drive the market growth.
Central venous catheterization is one of the most reliable options for therapy administration. Technological advancements are also facilitating adoption of central venous catheterization in medical care. Central venous lines are essential in the care of patients with severe diseases treated in surgical, intensive care, and oncological/hematological units. Catheters feature single, double, and multiple lumen, which facilitate administration of more than one treatment at once. Moreover, depending on the type of catheter, it may be left in place for weeks, months or years.
Market Dynamics
Initiatives taken by research associations and institutes for proper practice guidelines for appropriate insertions of central venous access are major factors driving the global central venous catheter market growth. In January 2020, the American Society of Anesthesiologists provided practice guidelines for central venous access to assist anesthesiologists and healthcare professionals. These guidelines serves purposes such as providing guidance for appropriate placement and management of central venous catheters, avoiding adverse outcomes associated with the central venous catheterization such as infections and mechanical complications, and improving management of injury arising from central venous catheterization.
Approvals of novel central venous catheters and increasing technological advancements in central venous catheter are major factors driving the global central venous catheter market growth. For instance in 2017, Access Scientific, LLC launched POWERWAND, a 16 gauge, single-lumen central venous catheter (CVC). The POWERWAND can be inserted swiftly and offers significantly faster flow rates.
Moreover, key players are strengthening their position in the global central venous catheter market by adopting strategies such as mergers and acquisitions and focusing on improving disease treatment with the help of central venous catheters. For instance, in 2017, Becton, Dickinson, and Company acquired C.R. Bard, Inc, the acquisition helped Becton, Dickinson, and Company to further strengthen its product portfolio and market positioning..
Key features of the study:
· This report provides in-depth analysis of the global central venous catheter market value, and provides market size (US$ 2,002.2 Mn) in 2020 and compound annual growth rate (CAGR 6.2%) for the forecast period (2020-2027), considering 2019 as the base year
· It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
· This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
· It profiles key players in the global central venous catheter market based on the following parameters – company overview, financial performance, device portfolio, market presence, distribution strategies, key developments, strategies, and future plans
· Key companies covered as a part of this study are AngioDynamics Inc., Lepu Medical Technology Co., Ltd, KIMAL PLC, Prodimed Benelux B.V, Terumo Corporation, Medtronic Plc, Teleflex Incorporated, Becton, Dickinson and Company, Amecath, ICU Medical, Inc., Edwards Lifesciences Corporation, Cook Group, Nipro Corporation, Bactiguard, Vygon (UK) Ltd, Guangdong Baihe Medical Technology Co., Ltd, Wujiang Evergreen EX/IM Co., Ltd, and ZOLL Medical Corporation
· Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future device launches, market expansion, and marketing tactics
· The global central venous catheter market report caters to various stakeholders in this industry including investors, suppliers, device manufacturers, distributors, new entrants, and financial analysts
· Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global central venous catheter market.
Detailed Segmentation:
· Global Central Venous Catheter Market, By Product Type :
o Peripherally Inserted Central Catheters (PICC)
o Implantable Ports
o Tunneled Central Venous Catheter
o Non-Tunneled Central Venous Catheter
· Global Central Venous Catheter, By Design :
o Single Lumen
o Double Lumen
· Global Central Venous Catheter, By Age Group :
o Adults
o Pediatric
o Geriatric
· Global Central Venous Catheter, By Procedure :
o Cardiovascular Procedure
o Chemotherapy Procedure
o Dialysis Procedure
· Global Central Venous Catheter, By End User :
o Hospitals
o Ambulatory Surgical Centers
o Specialty Clinics
· Global Endocrine Testing Market , By Region:
o North America
§ By Product Type:
§ Peripherally Inserted Central Catheters (PICC)
§ Implantable Ports
§ Tunneled Central Venous Catheter
§ Non-Tunneled Central Venous Catheter
§ By Design:
§ Single Lumen
§ Double Lumen
§ Multi Lumen
§ By Age Group:
§ Adult
§ Pediatric
§ Geriatric
§ By Procedure:
§ Cardiovascular Procedure
§ Chemotherapy Procedure
§ Dialysis Procedure
§ By End User:
§ Hospitals
§ Ambulatory Surgical Centre
§ Specialty Clinics
§ By Country:
§ U.S.
§ Canada
o Latin America
§ By Product Type:
§ Peripherally Inserted Central Catheters (PICC)
§ Implantable Ports
§ Tunneled Central Venous Catheter
§ Non-Tunneled Central Venous Catheter
§ By Design:
§ Single Lumen
§ Double Lumen
§ Multi Lumen
§ By Age Group:
§ Adult
§ Pediatric
§ Geriatric
§ By Procedure:
§ Cardiovascular Procedure
§ Chemotherapy Procedure
§ Dialysis Procedure
§ By End User:
§ Hospitals
§ Ambulatory Surgical Centre
§ Specialty Clinics
§ By Country:
§ Brazil
§ Mexico
§ Argentina
§ Rest of Latin America
o Europe
§ By Product Type:
§ Peripherally Inserted Central Catheters (PICC)
§ Implantable Ports
§ Tunneled Central Venous Catheter
§ Non-Tunneled Central Venous Catheter
§ By Design:
§ Single Lumen
§ Double Lumen
§ Multi Lumen
§ By Age Group:
§ Adult
§ Pediatric
§ Geriatric
§ By Procedure:
§ Cardiovascular Procedure
§ Chemotherapy Procedure
§ Dialysis Procedure
§ By End User:
§ Hospitals
§ Ambulatory Surgical Centre
§ Specialty Clinics
§ By Country:
§ Germany
§ U.K.
§ France
§ Italy
§ Spain
§ Russia
§ Rest of Europe
o Asia Pacific
§ By Product Type:
§ Peripherally Inserted Central Catheters (PICC)
§ Implantable Ports
§ Tunneled Central Venous Catheter
§ Non-Tunneled Central Venous Catheter
§ By Design:
§ Single Lumen
§ Double Lumen
§ Multi Lumen
§ By Age Group:
§ Adult
§ Pediatric
§ Geriatric
§ By Procedure:
§ Cardiovascular Procedure
§ Chemotherapy Procedure
§ Dialysis Procedure
§ By End User:
§ Hospitals
§ Ambulatory Surgical Centre
§ Specialty Clinics
§ By Country:
§ China
§ India
§ Japan
§ Australia
§ South Korea
§ ASEAN
§ Rest of Asia Pacific
o Middle East
§ By Product Type:
§ Peripherally Inserted Central Catheters (PICC)
§ Implantable Ports
§ Tunneled Central Venous Catheter
§ Non-Tunneled Central Venous Catheter
§ By Design:
§ Single Lumen
§ Double Lumen
§ Multi Lumen
§ By Age Group:
§ Adult
§ Pediatric
§ Geriatric
§ By Procedure:
§ Cardiovascular Procedure
§ Chemotherapy Procedure
§ Dialysis Procedure
§ By End User:
§ Hospitals
§ Ambulatory Surgical Centre
§ Specialty Clinics
§ By Country/Region:
§ GCC
§ Israel
§ Rest of Middle East
o Africa
§ By Product Type:
§ Peripherally Inserted Central Catheters (PICC)
§ Implantable Ports
§ Tunneled Central Venous Catheter
§ Non-Tunneled Central Venous Catheter
§ By Design:
§ Single Lumen
§ Double Lumen
§ Multi Lumen
§ By Age Group:
§ Adult
§ Pediatric
§ Geriatric
§ By Procedure:
§ Cardiovascular Procedure
§ Chemotherapy Procedure
§ Dialysis Procedure
§ By End User:
§ Hospitals
§ Ambulatory Surgical Centre
§ Specialty Clinics
§ By Country/Region:
§ South Africa
§ Central Africa
§ North Africa
· Company Profiles
o AngioDynamics Inc.*
§ Company Overview
§ Product Portfolio
§ Financial Performance
§ Key Highlights
§ Market Strategies
o Lepu Medical Technology Co., Ltd.
o KIMAL PLC
o Prodimed Benelux B.V
o Terumo Corporation
o Medtronic Plc
o Teleflex Incorporated.
o Becton, Dickinson and Company
o Amecath
o ICU Medical, Inc.
o Edwards Lifesciences Corporation
o Cook Group
o Nipro Corporation
o Bactiguard, Vygon (UK) Ltd
o Guangdong Baihe Medical Technology Co., Ltd
o Wujiang Evergreen EX/IM Co., Ltd
o ZOLL Medical Corporation
Request sample copy here : https://www.coherentmarketinsights.com/insight/request-sample/2400
Request PDF brochure here:
https://www.coherentmarketinsights.com/insight/request-pdf/2400
Click here to buy: https://www.coherentmarketinsights.com/insight/buy-now/2400
CMI Services: https://www.coherentmarketinsights.com/services
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.
What we provide:
· Customized Market Research Services
· Industry Analysis Services
· Business Consulting Services
· Market Intelligence Services
· Long term Engagement Model
· Country Specific Analysis
Contact Us:
Mr. Shah
Coherent Market Insights Pvt. Ltd.
Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S.
Phone: +1-206-701-6702
Email : [email protected]
Reference/Source: https://www.coherentmarketinsights.com/market-insight/central-venous-catheter-market-2400
0 notes
Link
For Immediate Release Press Release: Pune, India- 14th July , 2017 Global Precision Medicine Market – Estimate and Forecast Through (2015–2022) Description: The advancement and innovation of new healthcare technologies are developing the platform for the growth of precision medicine market. Since, the announcement of ‘Precision Medicine Initiative’ by the president Barack Obama in January end, 2015, a large number of research and developments are being done for the development of precise drugs, targeted therapeutics, and laboratory tests. Presently, the main focus of the government initiatives is toward oncology, but it is anticipated to target almost all therapeutic area affected by genetic mutations. The global precision medicine market is expected to reach $ 88 billion by 2022 at a CAGR of 12.0% during the forecast period. On the basis of sub-markets, Pharmacogenomics is by far the fastest growing segment of global precision medicine market and it is expected to reach $12.0 billion by 2022. Based on therapeutics, cancer commands the largest market share of global precision medicine market and it is expected to grow at a CAGR of 11.8% during the period 2015 to 2022. The Americas dominated the global market in 2014 and accounted for $20.63 billion due to the advancement of gene mapping technologies and increasing precision medicine solutions. Europe and APAC are estimated to show a high growth by the end of forecast period, where large numbers of developments in precision medicine have been noticed in the last few years are. In addition to this, APAC region is also predicted to grow at the highest CAGR of 14.34% from 2015 to 2022. For Sample Report @ http://ift.tt/2tnp86y @ Key Players The leading market players in the global precision medicine market include; Abbott Laboratories (U.S), Almac Group, Ltd. (U.K.), ASURAGEN, Inc. (U.S.), bioMérieux SA (France), Cepheid Inc. (U.S.), GE Healthcare (U.S), GlaxoSmithKline Plc (GSK) (U.K.), Johnson & Johnson (U.S) Medtronic (U.S.) and others. STUDY OBJECTIVES OF PRECISION MEDICINE MARKET DEVELOPMENT AND DEMAND FORECAST TO 2022 MARKET Ø To provide insights about factors, influencing and affecting the market growth. Ø To provide historically and forecast revenue of the market segments and sub-segments with respect to regional markets and their countries. Ø To provide historically and forecast revenue of the market segments based on products, and sub-segment for global precision medicine market. Ø To provide strategic profiling of key players in the market, comprehensively analyzing their market share, core competencies, and drawing a competitive landscape for the market. Ø To provide economic factors that influence the global precision medicine market. Target Audience • Pharmaceutical companies • Research Laboratories • Hospitals & Clinics • Service Suppliers • Potential Investors • Key executive (CEO and COO) and strategy growth manager Key Findings • Americas dominated the global precision medicine market in 2015; however, it is expected to grow at a CAGR of 11.6% during 2015 – 2022. • The companion diagnostics segment holds the largest share, with $10 billion value of the total market in 2015; while it is expected to reach $21.3 billion in 2022, at a CAGR of 13.4% for the period 2015-2022. • The cancer segments hold the largest share, with $21.1 billion value, of the total market in 2015; while it is expected to reach $46.3 billion in 2022, at a CAGR of 11.8% for the period 2015 – 2022. • Abbott Laboratories (U.S), GlaxoSmithKline Plc (GSK) (U.K.), Johnson & Johnson (U.S) Medtronic (U.S.), are so far the leading market players for precision medicine market globally Regional and Country Analysis of precision medicine Market Development and Demand Forecast to 2022 Market As per the MRFR analysis, the Americas precision medicine market is poised to reach $49.3 billion by 2022, to grow at a CAGR of around XX% during the forecasted period. The European market was valued at $ 9.2 billion in 2015, and expected to reach at $ 21.9 billion by 2022. Asia-Pacific continues to be the fastest growing region during the forecast period. The reports also cover country level analysis: • Americas o US o Canada • South America o U.S. • Europe o Germany o The U.K. • Asia-Pacific o China o Japan • Rest of the World (RoW) For any Enquiry write us @ http://ift.tt/2tRdKDp Table of Content 1 REPORT SCOPE 26 1.1 SCOPE OF THE STUDY 26 1.2 PRECISION MEDICINE: REPORT COVERAGE 27 1.3 RESEARCH METHODOLOGY 29 1.3.1 RESEARCH METHODOLOGY FOR THE GLOBAL MARKET STUDY 30 1.3.1.1 Geographical Analysis 30 1.3.1.2 Demand Side & Supply Side Analysis 31 1.3.1.3 Data Synthesis and Bridging 31 1.3.2 GLOBAL PRECISION MEDICINE: RESEARCH METHODOLOGY 32 1.3.3 KEY DATA POINT SOURCES 33 1.3.3.1 Data Points taken from Secondary Sources 33 1.3.3.2 Data Points taken from Primary Sources 33 1.4 REPORT DESCRIPTION 34 2 EXECUTIVE SUMMARY 38 3 MARKET OVERVIEW 42 3.1 INTRODUCTION 42 3.2 MARKET TIMELINE 42 3.3 KEY PARTICIPANTS, STRATEGIES & DEVELOPMENTS 50 3.3.1 GOVERNMENT AGENCIES 50 3.3.2 ACADEMIC INSTITUTIONS 50 3.3.3 DEVICE & SERVICE PROVIDERS 51 3.4 KEY MARKET STRATEGIES AND DEVELOPMENTS 51 3.4.1 INTRODUCTION 51 3.4.2 PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS 52 3.4.3 MERGERS & ACQUISITIONS 54 3.4.4 PRODUCT DEVELOPMENT AND LAUNCH 56 3.4.5 BUSINESS EXPANSION/CONTRACTS 57 3.4.6 PATENTS, APPROVALS AND CERTIFICATIONS 59 3.4.7 OTHERS (EVENTS & RECOGNITIONS) 60 4 MARKET DYNAMICS 61 4.1 INTRODUCTION 61 4.2 MARKET DRIVERS 62 4.2.1 PATIENTS INVOLVEMENT IN PERSONAL HEALTHCARE 62 4.2.2 TECHNOLOGIES DRIVING THE MARKET (E.G. NEXT-GENERATION SEQUENCING TECHNOLOGIES, ULTRA-HIGH THROUGHPUT SEQUENCING) 64 4.2.3 INCREASE IN GENETIC DISEASES 64 4.2.4 POTENTIAL FOR MORE TARGETED THERAPIES 65 4.2.5 INTEGRATION OF BIG DATA HEALTHCARE COMPANIES WITH PHARMA & BIOTECH COMPANIES 65 4.3 MARKET CHALLENGES 66 4.3.1 POTENTIAL THREAT TO PERSONAL DATA 66 4.3.2 HIGH DIAGNOSTIC COST AS A BARRIER 67 4.3.3 POTENTIAL RISK OF HARDWARE OR SOFTWARE FAILURE 68 4.3.4 STRINGENT REGULATIONS AND STANDARDS 68 4.3.5 LACK OF AWARENESS ABOUT THE POSSIBLE APPLICATIONS OF PRECISION MEDICINE 70 4.3.6 REIMBURSEMENT POLICIES AND REGULATORY FRAMEWORK 71 4.3.7 LIMITED KNOWLEDGE ABOUT THE APPLICATION OF TEST AND TECHNIQUES 71 4.3.8 LACK OF RESEARCH AND EVIDENCES CREATING HINDRANCES IN ITS APPLICATION 72 4.4 MARKET OPPORTUNITIES 73 4.4.1 INTRODUCTION OF PRECISION MEDICINE SOLUTIONS IN DEVELOPING ECONOMIES 73 4.4.2 DOWNSIZING THE COST OF GENOME SEQUENCING TO THREE DIGITS 74 5 INDUSTRY DYNAMICS 76 5.1 VALUE CHAIN ANALYSIS 76 5.1.1 DEVICE MANUFACTURER & DRUG PRODUCERS 77 5.1.2 HEALTHCARE PROVIDERS 77 5.1.3 HEALTHCARE ITS OR BIG DATA COMPANIES 77 5.1.4 REGULATORS 77 5.1.5 THIRD PARTY PAYERS 78 5.1.6 PATIENTS 78 5.2 PORTER FIVE FORCE ANALYSIS 78 5.2.1 BARGAINING POWER OF BUYER (PATIENT) 79 5.2.2 BARGAINING POWER OF SUPPLIER 80 5.2.3 THREAT FROM SUBSTITUTE 82 5.2.4 THREAT FROM A NEW ENTRANT 83 5.2.5 INTENSITY OF COMPETITIVE RIVALRY 84 Continued………… For accessing accurate and deep understanding and to gain latest insights and key developments in the area of your interest, we also have a list of conferences in which you will be interested in, for more information, cordially check : http://ift.tt/2uNLwag For updating knowledge or for thoroughly understanding various terminologies, we also have vast list of seminars for your reference, for more information cordially check : http://ift.tt/2tPQzK7
0 notes
Text
Global Non-Small Cell Lung Cancer (NSCLC) Treatment Market Share, Revenue, Demand and Forecast to 2025
Lung cancer is differentiated in to two types as non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Lung cancer is the uncontrolled growth of cells in the lung tissues. Majority of the lung cancer are NSCLC. Common symptoms are chest pain, wheezing, coughing up blood, hoarseness, weight loss, recurring bronchitis, loss of appetite, fatigue, shortness of breath, bone pain, swallowing difficulty and numbness of limbs. Increasing incidences of lung cancer due to smoking, air pollution (asbestos, cadmium and radon), HIV infection and population growth are few of the growth drivers of NSCLC market.
NSCLC has one of the most dynamic drug development pipelines in oncology with multiple targeted and biomarker-driven therapies. DRG expects the NSCLC therapy market to experience robust growth throughout the 2017-2027 forecast period. The biggest driver of market sales growth will be the continued uptake and anticipated label expansions of immune checkpoint inhibitors. EGFR and ALK inhibitors will also contribute to market growth following the first-line label expansions of Tagrisso and Alecensa, respectively.
For request sample: https://precisionbusinessinsights.com/request-sample/?product_id=23667
Global non-small cell lung cancer (NSCLC) treatment market was valued at US$ XX Mn in 2017 and expected to grow at XX% Compound Annual Growth Rate (CAGR) from 2018 to 2024
Increase in the prevalence of lung cancer is majorly driving the non-small cell lung cancer (NSCLC) treatment market. The growing awareness about the lung cancer diagnosis, treatment and the support from the government organizations expected to enhance the growth of the non-small cell lung cancer (NSCLC) treatment market. The adoption of the unhealthy lifestyle is also adding fuel for to the growth of the market. According to the American lung association, the number of deaths due to lung cancer has increased ~3.5% from ~152,156 cases in 1999 to ~157,499 in 2012 and according to American Society of cancer, non-small cell lung cancer accounts for ~85% to 90% of overall lung cancer cases. Owing to the larger patient pool, the non-small cell lung cancer (NSCLC) treatment market is expected to exhibit growth over the forecast period. However, the limited treatment options, and the availability of the generic drugs are likely to hinder the growth of the non-small cell lung cancer (NSCLC) treatment market.
Some of the players in the global non-small cell lung cancer (NSCLC) treatment market include:
· Bristol-Myers Squibb (U.S)
· AstraZeneca plc (U.K)
· Celgene Corporation (U.S)
· Boehringer Ingelheim (Germany)
· Novartis AG (Switzerland)
· Pfizer, Inc. (U.S)
· Eli Lilly and Company (U.S)
· Roche(Switzerland)
· Merck & Co.(U.S)
· Agennix AG (Germany)
The geographic segmentation of NSCLC market is into four regions such as Europe, North America, Asia Pacific and RoW. North America is expected to have largest market share followed by Europe in the forecasted period. Owing to increased smoking habits in developing countries Asia Pacific region can also be predicted to be a significant contributor to the NSCLC market. The rise in the patient pool is also adding fuel for the growth of the market in the region. Followed by North America are the regions of Europe and Asia Pacific. The growing penetration of the manufacturers in order to expand geographically in emerging markets expected to drive the growth of the market in these regions.
Precision Business Insights (PBI) in its report titled “Global non-small cell lung cancer (NSCLC) treatment market”: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 20XX-20XX and Forecast 20XX-20XX” assesses the market performance over seven years forecast period over 2019-2025. The report analyses the market value forecast.
Market Scope: Non-Small Cell Lung Cancer (NSCLC) Treatment Market
Non-small cell lung cancer (NSCLC) treatment market is segmented based on the drug class, application, and distribution channel
Based on the drug class, the market is segmented into the following:
· Microtubule Stabilizer
o Paclitaxel Protein Bound
o Docetaxel
· Angiogenesis Inhibitors
o Bevacizumab
o Ramucirumab
· Kinase Inhibitor
o Crizotinib
o Ceritinib
· Epidermal Growth Factor Receptor Blocker
o Erlotinib
o Afatinib
o Gefitinib
· PD-1/ PD-L1 Inhibitor
o Nivolumab
o Pembrolizumab
· Folate Antimetabolites
o Pemetrexed
o Others
Based on the application, the market is segmented into the following:
· Large Cell (Undifferentiated) Carcinoma
· Squamous Cell (Epidermoid) Carcinoma
· Adenocarcinoma
· Others
Based on the distribution channel, the market is segmented into the following:
· Hospital Pharmacies
· Retail Pharmacies
· Online Pharmacies
For more information:https://precisionbusinessinsights.com/market-reports/non-small-cell-lung-cancer-nsclc-treatment-market/
About Precision Business insights
Precision Business Insights is one of the leading market research and management consulting firm, run by a group of seasoned and highly dynamic market research professionals with a strong zeal to offer high-quality insights. Our company motto is to address client requirements in the best possible way and want to be a part of our client success. Relentless quest and continuous endeavor enable us to make new strides in market research and business consulting arena.
Contact to Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX Email: [email protected] Toll Free (US): +1-866-598-1553 Website @ https://www.precisionbusinessinsights.com
0 notes